

Expert report

Probable side effects to vaccination with Gardasil

Jesper Mehlsen, MD

Frederiksberg, Denmark

September 9th, 2024

Contents

Qualifications	3-4
Background	4
a. HPV in general	4
b. HPV vaccines	4
c. Autonomic nervous dysfunction	4
Methodology	4
Studies on post-Gardasil adverse events	5-6
Autoimmune conditions and Gardasil Vaccines	6-7
Improprieties by Merck or EMA regarding their investigation of Gardasil induced autoimmune conditions.	7-8
Epidemiologic studies on adverse events to HPV vaccination	8 - 15
a. Studies based on registers	8 - 10
b. Studies based primarily on symptoms	10 - 12
c. Studies based on adverse event reporting	12 – 14
d. Studies based on clinical studies by vaccine producers	14 - 15
e. Bradford Hill criteria applied to post-Gardasil vaccination autoimmune conditions including POTS	15 - 16
f. Summary and conclusion	16

QUALIFICATIONS

I graduated as a medical doctor from the University of Copenhagen, Denmark in 1979. As part of my training to become a specialist in Clinical Physiology and Nuclear Medicine, I did 11 years of postgraduate work in different specialties such as neurology, endocrinology, rheumatology, and urology.

After achieving my certification as a specialist in 1990, I primarily worked in the Department of Clinical Physiology and Nuclear Medicine at hospitals associated with the University of Copenhagen, becoming head of the Department at Frederiksberg Hospital in 1995. In that position, I developed a special interest in clinical and scientific work with patients having dysfunction of the autonomic nervous system. I helped establish tilt test procedures and teaching staff in several hospitals around Denmark. More than 8,500 tilt-tests with analysis of the autonomic, cardiovascular control have been performed by me or under my supervision. Working with Ph.D. students and their professor at the Department of Mathematics, North Carolina State University, I have developed mathematical models of autonomic cardiovascular control [1,2,3,4,5].

In 2010, I was asked to lead a Coordinating Research Center at Frederiksberg Hospital, where the focus was on collaboration with the pharmaceutical industry. I continued to see patients with autonomic nervous system dysfunction at the Syncope Center.

Prior to this appointment, I was Principal Investigator and headed steering committees in studies on hypertension, prevention of cardiovascular disease, and peripheral vascular disease. The main studies in the Coordinating Research Center were on Merck's HPV vaccines - primarily on Gardasil-9, with a few smaller studies on Gardasil 4. In total, the center had included 3,000+ patients in Gardasil studies. I acted as principal investigator in most and as National Coordinator in some of the studies on Gardasil in close collaboration with Merck's Danish Division (MSD Denmark).

In 2015, as a result of a dramatic increase in post-Gardasil vaccination injuries, the Danish Government established five regional centers to assess and treat patients with possible side effects to Gardasil vaccination. I was appointed to lead the "Unit for Patients with Unexplained Symptoms Possibly Related to HPV-vaccination" in the Capital Region of Denmark. A total of 845 patients were then referred to the clinic as well as others that had been referred to the Syncope Centre before 2015. In total, by 2016, the Danish Medicines Agency had received >2,300 reports on suspected adverse events among approximately 600,000 HPV-vaccinated women. From these reports, >1,000 were categorized as serious.

I left Frederiksberg Hospital (now Bispebjerg Frederiksberg Hospital) in January 2019 and have continued my scientific work at the National Hospital (Rigshospitalet), seeing patients in my private clinic. The clinical and scientific work is still focused on autonomic, cardiovascular dysfunction – in relation to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) – a diagnosis most of our patients in the "Unit for Patients with Unexplained Symptoms Possibly Related to HPV-vaccination" were given based on the International Consensus Criteria [6].

I was appointed President of the Danish Society of Clinical Physiology and Nuclear Medicine, 1996-99. I was Vice-president of the Danish Organization of Laboratory Medicine from 1995-98. I was a Member of the Board in the Danish Hypertension Society, 1994-2000. I am currently chairman of the European ME Clinician's Council and co-chairing the European ME Research Group.

According to Google Scholar, I have 333 publications of which 170+ are in peer-reviewed scientific journals. I have 20,000+ citations and my H-factor is 50 (an index based on the most cited papers and the number of citations received in other publications).

BACKGROUND

a. HPV in general

After being appointed to lead the Coordinating Research Center in 2010, I studied intensively human papilloma virus and the research showing the connection between HPV and cervical cancer of the uterus. I studied the development of cervical cancer through Denmark's unique screening program reducing the incidence of cervical cancer from 40 to 14 per 100,000 from 1960 to 2014 and the mortalities from 15 to 4 pr 100,000 in the same period.

b. HPV vaccines

As Principal Investigator in Merck's studies on the quadrivalent and the nonavalent Gardasil vaccines (Gardasil4 and Gardasil9), I was familiar with the background for the studies and the previous publications. This knowledge was further enhanced when I coauthored publications related to the studies run in the Coordinating Research Center [7,8,9,10].

c. Background on autonomic nervous dysfunction

By coincidence, I had become an expert on autonomic cardiovascular control while leading the Syncope Center at Frederiksberg Hospital, University of Copenhagen. That expertise was particularly useful when I served as a principal investigator in several of Merck's Gardasil4 and -9 studies.

I have worked clinically and scientifically with dysfunction of the autonomic nervous system for over 35 years. I coauthored my first publications in 1985 and have authored/coauthored 30+ scientific publications in the last 10 years related to autonomic nervous dysfunction.

I have therefore been able to observe firsthand, study, and describe the autonomic dysfunction suffered by patients following vaccination against HPV.

METHODOLOGY

Because of my professional experience and my prior research and publications as described above, I came to this task with a considerable amount of knowledge and understanding of the scientific issues surrounding Gardasil already. I am aware of much of the medical literature, both supporting and opposing viewpoints, and have necessarily kept up to date on the science in this area. For this assignment, I reviewed my own prior research, and I also conducted further research using a database called PubMed applying various search terms such as "Gardasil," "human papillomavirus," "autoimmune," "POTS," "orthostatic intolerance," and "dysautonomia." I analyzed the papers retrieved from my searches by focusing on: 1. the study type and objective; 2. the study population, including its size; 3. the outcome measures and

methods used to assess them; 4. the results, including consideration of risk and odds ratios to understand the strength of any associations found; 5. the conclusions by the authors; 6. the studies' limitations, including potential biases, methodological constraints, or issues with generalizability. I paid particular attention to opposing views (e.g. studies concluding Gardasil does not pose a risk) to ensure a balanced review of available evidence.

Using differential diagnoses in my practice treating dysautonomia patients following HPV vaccination, applying Bradford Hill criteria to studies finding an association between Gardasil and autoimmune conditions, dysautonomia and POTS, lab results, positive rechallenge and observations from my clinical experience and education, I analyze and arrive at conclusions to a reasonable degree of medical and scientific certainty. This process is consistent with the methodologies I have employed for decades in writing and publishing peer-reviewed medical journal articles, preparing briefings for regulatory bodies such as the EMA and the Danish Health Authority, and summarizing results from clinical trials, including those for Gardasil, in which I was a principal investigator.

Studies on post-Gardasil adverse events

In 2011, we saw the first patients complaining about symptoms starting shortly after their first, second, or third HPV vaccination. Their primary symptoms were orthostatic intolerance (lightheadedness, palpitations, fatigue, blurred vision, dizziness, nausea, chest discomfort, cognitive impairment, and near-fainting spells/syncope). As the number of patients with a similar history grew, we started to systematically collect data by questionnaires, standard blood tests, tests for autoimmunity, analyses of mitochondrial function, analyses of the immune system and measurements of autonomic cardiovascular control. The specialized analyses were performed by leading researchers in molecular biology and immunology from Denmark and Germany. We were funded for this work by a grant from the Danish Government.

In our 2015 publication on the first 53 referred patients, we concluded: *“We found consistency in the reported symptoms as well as between our findings and those described by others. Our findings neither confirm nor dismiss a causal link to the Q-HPV vaccine, but they suggest that further research is urgently warranted to clarify the pathophysiology behind the symptoms experienced in these patients and to evaluate the possibility and the nature of any causal link and hopefully establish targeted treatment options”* [11].

The National Board of Health reported on September 15th, 2015, to the Danish Parliament that regional clinics would be started to handle the possible side effects to HPV-vaccination [12]. In June 2015, I was appointed by the hospital administration to lead the clinic – “One Entry” Subtitled: “Investigation and possibly treatment of patients with unexplained symptoms that have occurred in temporal relation to an HPV vaccination” [13] – in the Capital Region of Denmark.

Our follow-up publication on 839 referred patients including control groups was published in a high-impact medical publication, the Journal of Autoimmunity, in 2022 [14]. The analyses lead to the conclusion that: *“This study has shown that girls and young women with probable side effects to HPV-vaccination have symptoms and biological markers compatible with an autoimmune disease closely resembling that seen in ME/CFS and subsets of long-COVID. Together with previous studies,*

demonstrating increase morbidity in this group of patients preceding vaccination, this raises the probability that prior disease may precondition some individuals for vaccine related adverse events. The HPV-vaccine possesses a strong immunogenicity, and it is suggested that possible vulnerability should be further investigated and considered when counselling for such vaccines.”

Autoimmune conditions and Gardasil vaccines

In developing vaccines there is always a trade-off regarding safety versus efficacy as expressed by the World Health Organization [15]: *“Vaccine efficacy refers to the ability of a vaccine to bring about the intended beneficial effects on vaccinated individuals in a defined population under ideal conditions of use. The potential benefits of an effective vaccine – e.g., promotion of health and well-being, and protection from illness and its physical, psychological, and socioeconomic consequences – must be weighed against the potential risk of an adverse event following immunization (AEFI) with that vaccine. Vaccine-associated risk is the probability of an adverse or unwanted outcome occurring, and the severity of the resulting harm to the health of vaccinated individuals in a defined population following immunization with a vaccine under ideal conditions of use”.*

Gardasil4 and -9 are very potent vaccines based on non-infectious recombinant type-specific L1 capsid proteins assembled into virus-like particles as immunogens that present an exterior surface closely mimicking the HPV virions. It is this multiplicity of L1 domains that confers the VLP antigen with substantial immunogenicity, which is further enhanced by concomitant immune modulators (adjuvants). Vaccine adjuvants are molecules or compounds that have intrinsic immunomodulatory properties and when administered in conjunction with an antigen, effectively potentiate the host antigen-specific immune responses compared to responses raised when antigen is given alone. Vaccination with Gardasil has a very high efficacy for generating potent antibodies to the vaccine’s included strains of HPV due to the combination of the VLP antigen and the aluminum containing adjuvant. Vaccines stimulate the immune system and activate first the non-specific (innate) system which subsequently converts to a specific immunity – in this case - against HPV. Stimulating the immune system activates the cell danger response resulting in the well-known symptoms of fatigue, low grade fever, headaches, and musculoskeletal pain. In most people, this response subsides within a day or two but in some cases, the danger response does not resolve [16]. The energy producing mitochondria change their function from producing the energy needed for normal bodily functions to a production of signaling molecules and reactive oxygen species designated to defend the body. Symptoms from muscle and nerve tissue are affected as they strongly depend on carbohydrate metabolism, which is diminished. Lactate stemming from anaerobic carbohydrate metabolism causes inflammation in muscle and nerve tissue accounting for muscle pain, headaches and probably also for brain fog. Part of the danger response is a lowered threshold for sensory information increasing the light and sound sensitivity, causing abnormal sensation like tingling, and increasing pain perception. Also, a part of the danger response is an imbalance in the normal autoantibodies directed at G-protein couple receptors [17] and in the Danish cohort, we found abnormal levels of autoantibodies directed against the adrenergic beta-2- and the muscarinic M-2-receptors in 92 per cent of the patients. These autoantibodies interfere with the normal autonomic control of internal

organs and are the probable cause of dysfunction of cardiovascular reflexes and blood pressure control, of gastrointestinal motility, of visual adaptation, and of exogenous glands. It is our opinion that postural tachycardia syndrome (POTS) is likely the result of the imbalance in cardiovascular control caused by the antibodies found in our cohort. The antibody pattern found in our cohort are like those found in other cohorts of HPV vaccinated and in POTS patients using different laboratories and different techniques [18,19,20]. I summarized and presented these analyses to Merck [20], Sanofi MSD and the Danish Health Authority [21]. (See Appendix 1)

Improprieties by Merck or EMA regarding their investigation of Gardasil induced autoimmune conditions.

To the best of my knowledge neither the producer – Merck - nor the European Medicines Agency (EMA) have properly conducted research into the relation between Gardasil vaccination and side effects such as POTS. As I was engaged in studies of Gardasil4 and -9 in close collaboration with Merck, I tried – December 2nd, 2014 - to draw the attention of Peter Aurup, MD, then Vice President and Head Global Clinical Trial Operations in Merck by e-mail to the fact that: *“Since late spring 2013, we have received a small number of referrals regarding patients with possible adverse reaction to HPV-vaccination. The background for referral has been signs and symptoms of autonomic dysfunction ...”*. Merck Denmark were receptive, but Merck USA, specifically Alain Luxembourg, discarded my concerns.

Based on literature reviews, data from the producers (Sanofi and Merck), and expert opinions, EMA declared in 2015 that there was no link between HPV vaccination and serious autoimmune or neurological adverse events. For some reason EMA ignored data provided by the WHO collaborating center in Uppsala, Sweden [23] and the subsequent safety concern with HPV vaccine [24] as well as other reports linking Gardasil to these adverse events.

I have personal knowledge concerning cases of POTS in the Gardasil clinical trial programs that an investigator working under my supervision attempted to report, but Merck would not accept the reports as adverse events.

Meanwhile, according to Gotzsche and Jorgensen, the reporting for Sanofi MSD to EMA was misleading [25] They wrote:

“On 15 May 2017, EMA Executive Director Guido Rasi explained to the EU Ombudsman that 'all studies submitted for the marketing authorization application for Gardasil were placebo controlled'. EMA's official report on POTS and CRPS also gives readers this impression and uses the term 'placebo cohorts' for the Gardasil trials.

“This is not true. None of the trials were truly placebo (ie, saline) controlled. In one trial, 597 children received a so-called 'placebo', which included all the excipients in the carrier solution. In another trial, of the nine-valent Gardasil 9, 306 participants received a saline placebo, but as they had all been vaccinated with the quadrivalent Gardasil earlier, those who did not tolerate the original HPV vaccine were likely not enrolled into the study. In the remaining trials, the control group received another vaccine, for example, against hepatitis A or B, which contain an

adjuvant similar to that in the HPV vaccines. EMA did not address this fundamental problem in its official report.”

“The use of active comparators may make it impossible to detect serious harms of the HPV vaccines in the randomized trials if the comparators cause the same or similar harms. This problem was criticised by two doctors external to EMA's expert group in the briefing note, but it was not mentioned in EMA's official report.”

Epidemiological studies on adverse events to Gardasil vaccination

a. Studies based on registers

i. The first major study was by Arnheim et al 2013 [26] and included 997 585 girls aged 10-17, among whom 296 826 received a total of 696 420 HPV-4 vaccine doses. Main outcome measures were incident hospital diagnosed autoimmune, neurological, and venous thromboembolic events (53 different outcomes) up to 180 days after each HP-4V vaccine dose. At least five vaccine exposed cases occurred in 29 and these were analyzed further. Whereas the rate ratios for 20 of 23 autoimmune events were not significantly increased, exposure to HPV-4 vaccine was significantly associated with Behcet’s syndrome, Raynaud’s disease, and type 1 diabetes. However, when they used their own “strength criteria,” these events were disregarded. They did not evaluate any symptoms of orthostatic intolerance, autonomic dysfunction or postural tachycardia – the latter being the most common form of orthostatic intolerance in young women [27] Although Denmark and Sweden are alike in many respects, including having similar healthcare systems and universal access to healthcare, differences in diagnostic coding practices might have influenced the ascertainment of cases. The vaccine coverage was 49% in Denmark and 18% in Sweden.

ii. Hviid et al published in 2020 [28] a study based on a nationwide cohort of Danish female participants aged 10-44 years in 2007-16 to evaluate the association between the quadrivalent human papillomavirus vaccine and chronic fatigue syndrome, complex regional pain syndrome, and postural orthostatic tachycardia syndrome in a self-controlled case series analysis. The register used to analyze the association between HPV vaccination and syndromes with autonomic dysfunction cannot be regarded as reflecting the true incidence of these syndromes. The validity of this study is questionable as the authors have lumped diagnostic codes thus mixing post-viral disease – such as mononucleosis which is prevalent in adolescents – with ME/CFS and including supraventricular tachycardia of any kind with POTS. The proper conclusion would be that they “failed to establish the reality of the effect under investigation.”

iii. Thomsen et al published in 2020 [29] a partly symptom-based register study using the Danish registry system and included data from 314,017 girls who were HPV-vaccinated at ages 11–17 years between 2008 and 2014. From all 442,229 girls aged 11–17 years in the source population, we sampled 177,724 unique girls who served as 314,017 matched unvaccinated comparators. These girls had not received an HPV vaccine on the index date of the HPV-vaccinated girls (56% of the 177,724 girls acted as an unvaccinated comparator to 1 vaccinated girl only, 25% to 2 vaccinated girls, and 19% to 3 or more vaccinated girls). A slight “healthy vaccinee effect” was observed; that is, girls who were vaccinated against HPV had a slightly lower prevalence of prior hospital-diagnosed comorbidity than unvaccinated girls. The main

study outcomes were the following types of hospital records, predefined in the protocol: a first hospital contact with abdominal pain, nonspecific pain, headache, malaise or fatigue (including CFS), tachycardia (four different ICD10 codes one of which was POTS), and hypotension or syncope. In absolute numbers they identified 10 cases of POTS in the group of unvaccinated girls and 6 in the vaccinated. They identified 9 cases of CFS in in the group of unvaccinated girls and so few in those vaccinated that they could not be reported due to data protection regulation (risk of being identifiable). The 95% confidence levels were 0.19 to 1.50 for POTS and 0.02 to 0.99 for CFS.

Interestingly, the same group of authors published data [30] on the same study as a poster and the results were quite different. In the poster they report on “all 184,597 HPV-vaccinated girls aged between 11 and 18 years in 2008-2014 in Denmark and 44,038 age-matched girls who did not receive HPV vaccine. All girls entered the study population at age 11.” They found significant differences between vaccinated and unvaccinated girls in the incidence rates of 6 different symptoms associated with POTS and ME/CFS – abdominal pain, unspecific pain, headache, hypotension/syncope, tachycardia, and malaise/fatigue:

TABLE 2. Incidence rates and adjusted incidence rate ratios of hospital contacts with selected diagnoses in girls exposed versus non-exposed to HPV vaccination

Outcome	HPV vaccine non-exposed		HPV vaccine exposed		Crude IRR (95% CI)	Adjusted* IRR (95% CI)
	n	Incidence rate /1.000 pyrs	n	Incidence rate /1.000 pyrs		
Abdominal Pain	2772	8.21	6423	10.36	1.07 (1.02-1.13)	1.08 (1.03-1.14)
Unspecific pain	337	0.95	920	1.39	1.18 (1.03-1.35)	1.26 (1.08-1.46)
Headache	513	1.45	1352	2.05	1.25 (1.12-1.40)	1.36 (1.21-1.54)
Hypotension/syncope	725	2.05	2458	3.75	1.42 (1.29-1.55)	1.39 (1.26-1.53)
Tachycardia	108	0.30	429	0.65	1.60 (1.28-2.02)	1.59 (1.24-2.04)
Malaise/fatigue	106	0.30	506	0.76	1.56 (1.24-1.96)	1.60 (1.25-2.04)
Chronic fatigue syndrome	11	0.03	6	0.01	0.17 (0.06-0.49)	0.20 (0.06-0.63)
Trauma	12330	92.4	14996	75.6	0.94 (0.92-0.96)	0.89 (0.87-0.92)
Diabetes	166	0.47	233	0.35	0.89 (0.72-1.11)	0.88 (0.70-1.10)
Cancer	41	0.12	85	0.13	1.00 (0.67-1.51)	0.94 (0.61-1.44)
Pneumonia	194	0.57	411	0.65	0.83 (0.69-1.01)	0.82 (0.67-1.00)
Asthma	577	1.72	1047	1.67	1.00 (0.89-1.12)	0.92 (0.82-1.04)
Appendicitis	683	1.94	1374	2.10	1.05 (0.95-1.16)	0.96 (0.86-1.07)

*Adjusted by Cox regression for: year of entry (2008-2014), history of asthma, diabetes, infections, or mental disorders, frequency of GP contacts, previous psychometric tests or talk therapy at GPs, previous psychologist or psychiatrist visit, education of parents (primary, secondary, higher), employment of parents (none, one, both), income of parents in DKR (<=490,000, 490,000-650,000, 650,000-840,000, >840,000), marital status of parents (married, other), and ethnicity (non-Danish, Danish)

They concluded this based on their results:

CONCLUSION

We found increased rates of a number of unspecific diagnoses in HPV-vaccinated vs. unvaccinated girls, but no increase on the population level after vaccine introduction. It is unclear if our results reflect causal vaccine effects, differences in care seeking, or lack of knowledge about diagnostic specificity, coding practice, and etiological window.

Comments: The girls were their own controls and thus appear both as unvaccinated and vaccinated, 177,724 were identified but the number of patients used in the analysis was 314,017 not 355,448 which would have been more logical (2 x 177,017), and the publication offers no explanation for this discrepancy. The age group included did not represent the total population of HPV vaccinated within the time frame used for the study as a catch-up vaccination program for adolescent girls and women up till the age of 27 years was running in that period. As has been pointed out by our group, the mean age of those seeking help in our unit for possible side effects to HPV-vaccination was 23.5 years and less than 6 per cent were in the original target age-group of 12 to 14 years [14]. This is a serious bias in their cohort selection.

In a somewhat larger and mostly overlapping group of vaccinees they found significant differences in six symptoms compared to an unvaccinated control group [30; copy of the poster in Appendix 3]. The results in terms of diagnoses were based on the Danish National Patient Registry but as pointed out earlier, the diagnoses of ME/CFS and POTS are almost non-existing in this registry. This is evident from the very small number of patients found by the study with these two diagnoses. The result – in statistical terms – is confidence intervals of such a width that they preclude meaningful analysis and the result being the so-called “error of the second kind” – in standard terms the chance of finding no difference between groups is almost 100 percent.

General comments on diagnosis-based register studies

The Danish Medicine Agency has in general discarded the epidemiological studies based on registers in their report to the European Medicine Agency and the rapporteurs on HPV vaccination [31]: “The data from these safety studies including a large number of women and with no evidence of increased risk of diseases are reassuring. However, a limitation in the studies is that the use of registers to identify outcome measures is highly dependent on diagnoses. The syndromes suspected as reactions to HPV-vaccination are often difficult to diagnose and has overlap in symptoms between diagnoses. Also, many cases report symptoms without a diagnosis. Such cases would not be identified in the currently published register studies.”

b. Studies based primarily on symptoms

i. Yaju and Tsubaki [32] are statisticians, and they reanalyzed data for a Japanese cohort of 30,793 women were included, comprising 21,034 vaccinated cases, 9,245 unvaccinated

controls (subtotal: 30,279). Data were originally obtained from a self-completed mail survey of 24 symptoms considered adverse events experienced in 70,000 girls/young women conducted in September 2015. Due to the change in policy regarding HPV-vaccinations in Japan the relation between age of the girls and vaccination status with the proportion of vaccinated girls varied from 14,6 per cent in the 15-year-old group to 70 percent in the 18-year-old group. This shift in proportion of vaccinated participants.


First, one possible explanation for these findings is the healthy vaccine effect bias [33]. These common symptoms are more prone to the healthy vaccine effect. For instance, young women in better health might be more likely to be vaccinated and women in worse health might be less likely to receive HPV vaccination. Therefore, events in the vaccinated group might be underestimated, whereas those in the unvaccinated group might be overestimated.

Second, the mean study period for the vaccinated cases was shorter than that for the unvaccinated controls. As a result of this difference, the event rates of the vaccinated cases were expected to be relatively under-estimated, compared to those of the unvaccinated controls.

They concluded [32] that: “Based on this analysis using data from the Nagoya Survey, a possible association between HPV vaccination and distinct symptoms, such as cognitive impairment or movement disorders, exists. A consistent causal relationship between HPV vaccination and these symptoms remains uncertain. However, given the seriousness of the symptoms, the authors believe that a more comprehensive and large-scale study is essential to confirm the safety of HPV vaccination.

ii. The study by Fukushima [34] is a descriptive, nationwide epidemiological survey to estimate the prevalence and incidence of diverse symptoms among Japanese adolescents without HPV vaccination. Participants were 11,037 medical departments in hospitals selected nationwide by stratified random sampling. Eligible patients had to satisfy four criteria: aged 12–18 years upon visiting hospital; having at least one of four symptoms pain or sensory dysfunction, motor dysfunction, autonomic dysfunction, or cognitive impairment); symptoms persisting for at least 3 months; and influence attendance at school or work. They extracted data of patients with diverse symptoms like those after HPV-vaccination while considering opinions of doctors in charge. Of the 18,302 departments selected for the first-stage survey, 11,037 (60.3%) responded. The 6-month period prevalence of diverse symptoms was 19.8 per 100,000 for boys and 40.1 per 100,000 for girls. The prevalence for “never vaccinated” was 20.2 per 100,000, for those with symptoms following HPV vaccination 27.8 per 100,000. The prevalence among those with unknown vaccine status could not be estimated. Fukushima et al concluded that adolescent Japanese girls without HPV vaccination also visited hospitals with diverse symptoms similar to those following HPV vaccination.

Comments: Including girls with only one or very few symptoms in the group would lead to a skewed distribution which they do not discuss. In our cohort 80 per cent of the included had more than 10 symptoms and looking at Fukushima’s data will reveal a more than doubling of the relative difference between vaccinated and unvaccinated of having > 1 symptom to > 10 symptoms (see below)



c. Studies based on adverse event reports

i. The study by Chao C et al [35] included 189,629 women of all ages who received at least one dose of HPV4 between 08/2006 and 03/2008. The majority (99%) of these women were in the indicated age range (9–26 years). Women in the autoimmune surveillance were followed up to 180 days (referred to as the risk period, excluding day of vaccination) after each dose of HPV4. Autoimmune conditions of interest were prespecified and composed of three groups: (i) rheumatologic/autoimmune disorders, including immune thrombocytopenia (ITP), autoimmune hemolytic anemia, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA), (ii) autoimmune endocrine conditions, including type 1 diabetes, Hashimoto's disease and Graves' disease, and (iii) autoimmune neurological/ophthalmic conditions, including multiple sclerosis (MS), acute disseminated encephalomyelitis, other demyelinating diseases of the central nervous system, vaccine-associated demyelination, Guillain-Barré syndrome, neuromyelitis optica, optic neuritis and uveitis. 1014 potential new-onset cases were electronically identified; 719 were eligible for case review; 31–40% were confirmed as new onset. This result in a group of 223 – 288 individual confirmed cases and except for Hashimoto's disease none of the estimated incidence risk ratios were significant. They did not analyze autoimmune autonomic dysfunction in general or POTS and syncope. In the study Chao et al want to show the prevalence of specific autoimmune disease in subjects vaccinated with Gardasil-4. They prespecified three groups of autoimmune diseases and carefully reviewed the new onset cases in the vaccinated group.

To attain an estimate of new-onset cases within the unvaccinated control group they used a mathematical model often applied to account for non-responders. To build the model they apparently used data from the vaccinated and evaluated group and applied the model both to unvaccinated controls and for those not sampled, vaccinated, potential cases. This approach has a high risk of *circulus in probando*, which is a logical fallacy in which the reasoner begins with what they are trying to end with. When combined with the fact that the project was financed by the producer of the vaccine invalidates the results obtained.

ii. In the study by Felicetti et al [36], all spontaneous reports of vasculitis following immunization between January 2003 and June 2014 were retrieved from Eudravigilance (EV), the Vaccine Adverse Event Reporting System (VAERS), and VigiBase®. A Standard MedDRA Query (SMQ) for vasculitis was used and vaccine types were categorized using the Anatomical Therapeutic Chemical classification system. They retrieved 1797 reports of vasculitis in EV, 1171 in VAERS, and 2606 in VigiBase®. Vasculitis was predominantly reported in children aged 1–17 years. The generic term “vasculitis” was the most frequently reported AEFI in this category across the three databases (range 21.9% to 27.5% of all reported vasculitis for vaccines). For the more specific terms, Henoch–Schoenlein Purpura (HSP) was most frequently reported, (19.1% on average), followed by Kawasaki disease (KD) (16.1% on average) and polymyalgia rheumatica (PMR) (9.2% on average). Less frequently reported subtypes were cutaneous vasculitis (CuV), vasculitis of the central nervous system (CNS-V), and Behcet’s syndrome (BS). BS was most frequently reported after hepatitis and HPV vaccines and CNS-V after HPV vaccines.

iii. The study by Chandler et al [24] aimed at exploring global reporting patterns for HPV vaccine for subgroups of reports with similar adverse event (AE) profiles. All individual case safety reports for HPV vaccines in VigiBase® until 1 January 2015 were identified. A statistical cluster analysis algorithm was used to identify natural groupings based on AE profiles in a data-driven exploratory analysis. Clinical assessment of the clusters was performed to identify clusters relevant to current safety concerns. Fifty-four clusters containing at least five reports were identified. The four largest clusters included 71 % of the analyzed HPV reports and described AEs included in the product label. Four smaller clusters were identified to include case reports relevant to ongoing safety concerns (total of 694 cases). In all four of these clusters, the most reported AE terms were headache, dizziness, and fatigue or syncope; three of these four AE terms were described in >50 % of the reports included in the clusters. These clusters had a higher proportion of serious cases compared with HPV reports overall. Furthermore, only a minority of reports included in these clusters included AE terms of diagnoses to explain the symptoms. Using proportional reporting ratios, the combination of headache and dizziness with either fatigue or syncope was found to be more commonly reported in HPV vaccine reports compared with non-HPV vaccine reports for females aged 9–25 years. This disproportionality remained when results were stratified by age and when those countries reporting the signals of CRPS (Japan) and POTS (Denmark) were excluded. They concluded that the study revealed additional reports of AEs following HPV vaccination that are serious in nature and describe symptoms that overlap those reported in cases from the recent safety signals (POTS, CRPS, and CFS), but which do not report explicit diagnoses.

iv. Geir and Geir undertook two epidemiological studies to evaluate concerns about the potential for HPV4 vaccination to induce serious autoimmune adverse events (SAAEs) [37,38]. In the first study [37], the vaccine adverse event reporting system (VAERS) database was examined for adverse event reports associated with vaccines administered from January 2006 through December 2012 to recipients between 18 and 39 years old with a listed residence in the USA and a specified female gender. It was observed that cases with the SAAE outcomes of gastroenteritis, arthritis, systemic lupus erythematosus, vasculitis, alopecia, or CNS conditions were significantly more likely than controls to have received HPV4 vaccine. Cases with the outcomes of Guillain-Barre syndrome, thrombocytopenia, infection, conjunctivitis, or diarrhea

were no more likely than controls to have received HPV4 vaccine. Cases with the general health outcomes were no more likely than controls to have received HPV4 vaccine.

v. In their second study [38], Geir and Geir extended their first study by expanding the study period (2006 to 2014) and the age interval 6–39-year-old recipients. In this study, they found cases with the serious autoimmune adverse event (SAAE) outcomes of with syncope, gastroenteritis, rheumatoid arthritis, thrombocytopenia, systemic lupus erythematosus, vasculitis, alopecia, CNS demyelinating conditions, ovarian damage, or irritable bowel syndrome were significantly more likely than controls to have received HPV4 vaccine. Cases with the outcome of Guillain-Barre syndrome were no more likely than controls to have received HPV4 vaccine. Cases with Guillain-Barre syndrome, infection, conjunctivitis, diarrhea, or pneumonia were no more likely than controls to have received HPV4 vaccine.

d. Studies based on clinical studies by vaccine producers

i. Jorgensen et al [25] showed that careful analyses of the data from clinical studies conducted by the vaccine producers would have revealed possible side effects. Joergensen et al published a review study aimed at assessing the benefits and harms of the human HPV vaccines [39]. They obtained 24 clinical study reports of 58,412 pages from EMA/Merck and GlaxoSmithKline for 22 industry trials and 2 industry follow-up studies - 17 Cervarix™, 5 Gardasil™, 1 Gardasil 9™ and 1 monovalent Merck HPV type 16 vaccine with a total of 95,670 participants (79,102 females and 16,568 males aged 8–72 years). Two researchers extracted data and judged risk of bias with the Cochrane tool. Risk ratio (RR) estimates were pooled using random-effects meta-analysis. Clinically relevant outcomes in intention to treat populations—including serious and general harms.

Twenty-four of 50 eligible clinical study reports were obtained with 58,412 pages of 22 trials and 2 follow-up studies including 95,670 participants: 79,102 females and 16,568 males age 8–72; 393,194 person-years; and 49 months mean weighted follow-up. Serious harms were incompletely reported for 72% of participants. Nearly all (99%) control participants received active comparators. No clinical study report included complete case report forms.

The HPV vaccines did not significantly increase fatal (RR 1.19 (95% CI 0.65 to 2.19)) or serious harms (RR 1.01 (95% CI 0.94 to 1.08)), and no individual fatal or serious harm classified with a MedDRA-preferred term was significantly increased or decreased by the HPV vaccines.

The HPV vaccines increased new onset back pain RR 1.15 (95% CI 1.00 to 1.33). The HPV vaccines increased general harms RR 1.07 (95% CI 1.03 to 1.11) — especially myalgia RR 1.41 (95% CI 1.24 to 1.60), fatigue RR 1.13 (95% CI 1.08 to 1.18), and headache RR 1.06 (95% CI 1.02 to 1.11). The HPV vaccines increased serious nervous system disorders grouped in the MedDRA system organ class RR 1.49 (95% CI 1.02 to 2.16) and decreased new onset vascular disorders grouped in the MedDRA system organ class RR 0.80 (95% CI 0.67 to 0.94).

Cases of anaphylaxis and syncope were evenly distributed. There were no cases of chronic fatigue syndrome (CFS), complex regional pain syndrome (CRPS), Guillain-Barré syndrome (GBS) or postural tachycardia syndrome (POTS), but there was one case of premature ovarian failure (POF) in the HPV vaccine group. Post hoc exploratory analyses of harms of special interest yielded the following results: “The serious harms that were judged ‘definitely associated’ with POTS or CRPS by the blinded physician were increased by the HPV vaccines,

both for POTS (56 vs. 26, RR 1.92 [95% CI 1.21 to 3.07], NNH 1073, P = 0.006, I2 = 0%) and CRPS (95 vs. 57, RR 1.54 [95% CI 1.11 to 2.14], NNH 906, P = 0.010, I2 = 0%). The new onset diseases that were judged 'definitely associated' with POTS were also increased by the HPV vaccines (3675 vs. 3352, RR 1.08 [95% CI 1.01 to 1.15], NNH 144, P = 0.03, I2 = 29%).

Bradford Hill criteria applied to post-Gardasil vaccination autoimmune conditions including POTS.

- a. **Strength:** A small association does not mean that there is not a causal effect, though the larger the association, the more likely that it is causal. *An association between HPV-vaccine and symptoms of chronic inflammation has been found in at least three cohorts [14,34,35] – one in Denmark and two in Japan. The systematic review by Joergensen et al [39] showed autoimmune conditions such as POTS and CRPS were significantly associated with HPV-vaccination.*
- b. **Consistency:** Consistent findings observed by different persons in different places with different samples strengthens the likelihood of an effect. *POTS associated with HPV-vaccination has been reported in case reports [18,40,41], The findings in the two large cohorts were observed by independent observers and cases reported by other observers [42,43] show similar findings.*
- c. **Specificity:** Causation is likely if there is a very specific population at a specific site and disease with no other likely explanation. The more specific an association between a factor and an effect is, the bigger the probability of a causal relationship. *Adverse events are reported from a specific population of girls and young women vaccinated against HPV [14,34,35,42,43].*
- d. **Temporality:** The effect has to occur after the cause (and if there is an expected delay between the cause and expected effect, then the effect must occur after that delay). *There is a time delay between the cause (HPV-vaccination) and the effect (occurrence of symptoms). [14,32,35]*
- e. **Biological gradient:** Greater exposure should generally lead to greater incidence of the effect. However, in some cases, the mere presence of the factor can trigger the effect. In other cases, an inverse proportion is observed: greater exposure leads to lower incidence. *Adverse events were more likely after the second and third dose of the vaccine. [12]*
- f. **Plausibility:** A plausible mechanism between cause and effect is helpful (but Hill noted that knowledge of the mechanism is limited by current knowledge). *Vaccines containing adjuvants have been linked to an increased risk of autoimmune/-inflammatory adverse events following immunization [36]. The review by Guimarães et al [44] stated: "there is evidence of vaccine-induced autoimmunity and adjuvant induced autoimmunity in both experimental models as well as human patients" [50]*
- g. **Coherence:** Coherence between epidemiological and laboratory findings increases the likelihood of an effect. However, Hill noted that "... lack of such [laboratory] evidence cannot nullify the epidemiological effect on associations." *Epidemiological findings cohere [37,38] with the clinical observations.*
- h. **Experiment:** "Occasionally it is possible to appeal to experimental evidence." *Experimental evidence for a risk of cross-reactivity have been published [45].*

- i. Analogy: The use of analogies or similarities between the observed association and any other associations. *Other types of vaccines have caused long-term adverse events in other populations [46,47].*

Summary and conclusion

Cohort and case studies have shown probable connection between HPV vaccination and autoimmune conditions and Postural Tachycardia syndrome as well as other generalized inflammatory conditions.

Epidemiological studies based on data derived from national registers are not useful in detecting such conditions as expressed by the Danish Medicine Agency: “a limitation in the studies is that the use of registers to identify outcome measures is highly dependent on diagnoses. The syndromes suspected as reactions to HPV-vaccination are often difficult to diagnose and has overlap in symptoms between diagnoses.”

Epidemiological studies based on symptoms are not useful when reporting on single symptoms as autoimmune conditions, and POTS, result in several symptoms and because single symptoms in a cohort of adolescents are very common hampering the probability of detecting any differences between vaccinees and their controls is very low.

Epidemiological studies based on adverse event reports have shown clear signals of autoimmune conditions associated with HPV vaccination. Reexamining the protocols of HPV vaccines prior to approval for general use have supported the independent analysis of adverse event reports.

As expressed by Chandler, et al [48]: “The randomized controlled trials upon which licensure is based and the observational epidemiological studies by which post-marketing signals are investigated provide only population-based estimations of risk. No epidemiological study can answer the question “Did this vaccine cause this event in this patient?” [48]. The Committee to Review Adverse Effects of Vaccines stated in 2011: “Epidemiologic analyses are usually unable to detect an increased or decreased risk that is small and epidemiologic analyses also cannot identify with certainty which individual in a population at risk will develop a given condition” [49]. In a more recent analysis [5], Gvozdenović et al stated that as “many epidemiological studies are observational in their design, and unlike randomized controlled trials where similarity of groups can be experimentally attained, comparability of groups can be difficult or even impossible to demonstrate. This renders causal inference in these cases challenging and conditional on unverifiable assumptions.”

Based on my education, experience, research, investigation, analyses, a review of the literature, and the material identified in this report, it is my opinion to a reasonable degree of medical and scientific certainty that Gardasil has been the probable cause of POTS and an autoimmune condition resembling myalgic encephalomyelitis (ME/CFS) and Post-COVID-19 syndrome. Dysfunction of the autonomic nervous system induced by Gardasil is prominent in these syndromes with manifestations of severe orthostatic intolerance i.e. POTS.

Frederiksberg, September 9th 2024

A handwritten signature in blue ink, appearing to read 'J. Mehlsen', is written over a horizontal line.

Jesper Mehlsen

References

1. ND Williams, O Wind-Willassen, AA Wright, J Mehlsen, JT Ottesen. Patient-specific modelling of head-up tilt. *Mathematical medicine and biology: a journal of the IMA* 31 (4), 365-392. 2014
2. JT Ottesen, J Mehlsen, MS Olufsen Structural correlation method for model reduction and practical estimation of patient specific parameters illustrated on heart rate regulation. *Mathematical biosciences* 257, 50-59 2014
3. B Matzuka, J Mehlsen, H Tran, MS Olufsen Using Kalman filtering to predict time-varying parameters in a model predicting baroreflex regulation during head-up tilt. *IEEE Transactions on Biomedical Engineering* 62 (8), 1992-2000. 2015
4. Brady R, Frank-Ito DO, Tran HT, Janum S, Møller K, Brix S, Ottesen JT, Mehlsen J, Olufsen MS. Personalized mathematical model of endotoxin-induced inflammatory responses in young men and associated changes in heart rate variability. *Math Model Nat Phenom.* 2018; 13(5): 1–21.
5. EB Randall, A Billeschou, LS Brinth, J Mehlsen, MS Olufsen A model-based analysis of autonomic nervous function in response to the Valsalva maneuver. *Journal of Applied Physiology* 127 (5), 1386-1402. 2019.
6. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisnik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S. Myalgic encephalomyelitis: International
7. D Ferris, R Samakoses, SL Block, E Lazcano-Ponce, JA Restrepo, KS Reisinger, J Mehlsen, A Chatterjee, O-E Iversen, HL Sings, Q Shou, TA Sausser, A Saah. Long-term study of a quadrivalent human papillomavirus vaccine. *Pediatrics* 134 (3), e657-e665. 2014
8. EA Joura, AR Giuliano, OE Iversen, C Bouchard, C Mao, J Mehlsen, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *New England Journal of Medicine* 372 (8), 711-723. 2015
9. P Kosalaraksa, J Mehlsen, T Vesikari, A Forstén, K Helm, P van Damme, EA Joura, K Ciprero, R Maansson, A Luxembourg, A Sobanjo-ter Meulen. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy ... *The Pediatric Infectious Disease Journal* 34 (6), 627-634. 2015
10. D G Ferris, R Samakoses, SL Block, E Lazcano-Ponce, JA Restrepo, J Mehlsen, A Chatterjee, O-E Iversen, A Joshi, J-Li Chu, AL Krick, A Saah, R Das. 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. ...*Pediatrics* 140 (6). 2017.
11. L Brinth, K Pors, AAG Hoppe, I Badreldin, J Mehlsen. Is chronic fatigue syndrome/myalgic encephalomyelitis a relevant diagnosis in patients with suspected side effects to human papilloma virus vaccine. *Int J Vaccines Vaccin* 1 (1), 00003. 2015.
12. Status of the Danish Health Authority's initiatives within surveillance, investigation, and treatment of possible side effects of the HPV vaccine. September 15th, 2015.
<https://www.ft.dk/samling/20142/almdel/suu/bilag/68/1548223.pdf> (in Danish)
13. <https://www.sundhed.dk/sundhedsfaglig/information-til-praksis/sjaelland/almen-praksis/patientbehandling/patientforloeb/henvisning-visitiation/henvisningsvejledninger/medicinsk-henvisning/oevrige-medicinske-specialer/hpv-vaccination-bivirkninger/> (in Danish)
<https://vaccine-safety-training.org/balancing-efficacy-and-safety.html>
14. Mehlsen J, Brinth L, Pors K, Varming K, Wallukat G, Olsen RKJ. Autoimmunity in patients reporting long-term complications after exposure to human papilloma virus vaccination. *J Autoimmun.* 133:102921. 2022
15. <https://vaccine-safety-training.org/balancing-efficacy-and-safety.html>
16. Naviaux RK. Metabolic features of the cell danger response. *Mitochondrion.* 16: 7-17. 2014.
17. Riemenkasten G Petersen F, Heidicke H. What Makes Antibodies Against G Protein-Coupled Receptors so Special? A Novel Concept to Understand Chronic Diseases *Frontiers in Immunology* 2020 11.

18. Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. *Eur J Neurol*. 21(1):135-9. 2014
19. Gunning WT 3rd, Kvale H, Kramer PM, et al. Postural Orthostatic Tachycardia Syndrome Is Associated with Elevated G-Protein Coupled Receptor Autoantibodies. *J Am Heart Assoc*. 8(18): e013602. 2019.
20. Li H, Zhang G, Forsythe E, Okamoto LE, Yu X. Implications of Antimuscarinic Autoantibodies in Postural Tachycardia Syndrome. *J Cardiovasc Transl Res*. 15:438-440. 2022.
21. Mehlsen J 2015 Powerpoint presentations you did to Merck, Denmark. PowerPoint attached
22. Mehlsen J 2015 PowerPoint presentation to Sanofi personnel and OBGYN-specialists. PowerPoint attached.
23. Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Norén GN. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®. *Drug Saf*. 2017; 40(1):81-90.
24. Chandler RE, Edwards IR, Lindquist M. Comment on "Safety of Human Papillomavirus Vaccines: An Updated Review." *Drug Saf*. 2018 May;41(5):537-538.
25. Gotzsche P, Jorgensen KJ. EMA's mishandling of an investigation into suspected serious neurological harms of HPV vaccines *Br Med J Epub ahead of print*: 2020. doi:10.1136/bmjebm-2020-111470
26. Arnheim-Dahlström L, Pasternak B, Svanström H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. *BMJ*. 2013; 347:f5906.
27. Bryarly M, Phillips LT, Fu Q, et al. Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar. *J Am Coll Cardiol*. 2019;73(10):1207-28.
28. Hviid A, Thorsen NM, Valentin-Branth P, et al. Association between quadrivalent human papillomavirus vaccination and selected syndromes with autonomic dysfunction in Danish females: population based, self-controlled, case series analysis. *BMJ*2020 370:m2930
29. Thomsen RW, Öztürk B, Pedersen L, et al. Hospital Records of Pain, Fatigue, or Circulatory Symptoms in Girls Exposed to Human Papillomavirus Vaccination: Cohort, Self-Controlled Case Series, and Population Time Trend Studies. *Am J Epidemiol*. 2020 189:277–285.
30. Thomsen RW, Öztürk B, Pedersen L, et al Unspecific ICD-10 hospital discharge diagnoses after HPV vaccination: A nationwide matched cohort and time series study. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - Prag, Czech Republic Aug 2018.
31. Danish Medicine Agency. Report for EMA and rapporteurs regarding HPV. 04/09/2015
32. Yaju Y, Tsubaki H. Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events. *Japan Journal of Nursing Science* 2019. DOI: 10.1111/jjns.12258
33. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. *J Gen Intern Med*. 2011 May;26(5):546-50
34. Fukushima W, Hara M, Kitamura Y, et al. A Nationwide Epidemiological Survey of Adolescent Patients with Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan, *Journal of Epidemiology*, 2022, 32: 34-43.
35. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. *J Intern Med* 2012 271:193-203
36. Felicetti P, Trotta F, Bonetto C, et al. Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. *Vaccine*. 2016; 34(51):6634-6640.
37. Geier DA, Geier MR. A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. *Clin Rheumatol* 2015 34:1225–1231.

38. Geier DA, Geier MR. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case–control assessment of the vaccine adverse event reporting system (VAERS) database. *Immunol Res* 2017 65:46–54.
39. Jorgensen L, Gotzsche PC, Jefferson T. Benefits and harms of the human papillomavirus vaccines: systematic review of industry and nonindustry study reports *Systematic reviews* 2020, 9(1):43.
40. Kinoshita T, Abe RT, Hineno A, Tsunekawa K, Nakane S, Ikeda S Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. *Intern Med.* 2014;53(19):2185-200.
41. Hineno A, Ikeda S, Scheibenbogen C, et al. Autoantibodies against Autonomic Nerve Receptors in Adolescent Japanese Girls after Immunization with Human Papillomavirus Vaccine. *Ann Arthritis Clin Rheumatol.* 2019; 2(2): 1014
42. Blitshteyn S. Postural tachycardia syndrome after vaccination with Gardasil. *Eur J Neurol* 2010 17: e52.
43. Tomljenovic L, et al. Postural Orthostatic Tachycardia with Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants”: Case Report and Literature Review. *J Invest Med High Impact Case Reports* 2014 p: 1–8
44. Cerpa-Cruz S, Paredes-Casillas P, Landeros Navarro E, et al. Adverse events following immunization with vaccines containing adjuvants. *Immunol Res.* 2013; 56: 299-303.
45. Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. *Pharmacol Res.* 2015 Oct;100:190-209.
46. Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. *J Exp Ther Oncol.* 2009 8: 65-76
47. Stowe J, Andres N, Gringras P, et al. Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case coverage study. *PLoS Med* 2020 17(9): e1003225.
48. Hwang SM, Choe KW, Cho SH, et al. The adverse events of influenza A (H1N1) vaccination and its risk factors in healthcare personnel in 18 military healthcare units in Korea. *Jpn J Infect Dis.*64(3):183-9. 2011
49. Chandler RE, Edwards IR, Lindquist M. Comment on "Safety of Human Papillomavirus Vaccines: An Updated Review." *Drug Saf.* 2018 May;41(5):537-538.
50. Stratton K, Ford A, Rusch E, et al., editors. Committee to Review Adverse Effects of Vaccines; Institute of Medicine. Washington (DC): National Academies Press (US); 2011.
51. Gvozdrenović, E., Malvisi, L., Cinconze, E. *et al.* Causal inference concepts applied to three observational studies in the context of vaccine development: from theory to practice. *BMC Med Res Methodol* **21**, 35 (2021).

Appendix 1:

Informationsmøde for patienter mistænkt for bivirkninger til HPV-vaccine

Torsdag den 7. maj 2015

Kl. 19:30 - 21:00

Appendix 3

Unspecific ICD-10 Hospital Discharge Diagnoses After HPV Vaccination: A Nationwide Matched Cohort And Time Series Study

Reimar W Thomsen¹, Buket Öztürk¹, Lars Pedersen¹,
Sia K Nicolaisen¹, Irene Petersen², Kim Varming³,
Jørn Olsen¹ and Henrik T Sørensen¹

¹ Aarhus University Hospital, Aarhus, Denmark.
² University College London, London, United Kingdom
³ Aalborg University Hospital, Aalborg, Denmark.

Background

Since inclusion of HPV vaccination in pediatric care in the late 2000s, diffuse autonomic symptoms have emerged among vaccinated girls, which undermine public confidence in the vaccine.

Aim

To examine the risk of unspecific ICD-10 discharge diagnoses in HPV-vaccinated vs unvaccinated girls made during hospital contacts (outpatient clinics, emergency departments, or inpatient admissions), including pain, malaise/fatigue, hypotension/syncope, and tachycardia. We also examined nationwide time trends in these diagnoses in Danish girls and boys.

Methods

Cohort outcome analysis and time series study based on the Danish Civil Registration System, National Patient Registry, Health Insurance Service Registry, Prescription Registry, and labour market databases. The study included all 184,597 HPV-vaccinated girls aged between 11 and 18 years in 2008-2014 in Denmark and 44,038 age-matched girls who did not receive HPV vaccine. All girls entered the study population at age 11. Exposure to the HPV vaccine was a time-varying variable. Incidence rates of discharge diagnoses were assessed, using Cox regression to adjust for comorbid conditions, prior healthcare contacts, ethnicity, and parental education, employment, income, and marital status.

Results

Between 2008 and 2012, more than 85% of 11-year-old girls received the HPV vaccine, usually before they turned 13 (94%). By 2014 only 28% of girls received this vaccine. HPV vaccinated girls had slightly less comorbidity at baseline, had socioeconomically better off parents, and were less likely to be immigrants (TABLE 1). Adjusted incidence rate ratios (IRRs) in HPV vaccine-exposed vs unexposed girls were increased, as follows: 1.08 (95% CI 1.03-1.14) for abdominal pain, 1.26 (1.08-1.46) for unspecific pain, 1.36 (1.21-1.54) for headache, 1.39 (1.26-1.53) for hypotension/syncope, 1.59 (1.24-2.04) for tachycardia, and 1.60 (1.25-2.04) for malaise/fatigue (TABLE 2). The IRR for death was clearly decreased at 0.39 (0.23-0.65). IRRs for negative control outcomes (trauma, cancer, diabetes, pneumonia, asthma, appendicitis) were close to 1.0 (TABLE 2). In population time-trend analyses, we observed a steady increase in the above diagnoses in both girls and (largely HPV-unvaccinated) boys between 2002 and 2016, unrelated to HPV vaccination introduction in 2008 (FIGURE 1).

FIGURE 1. Time trends in nationwide incidence per 100,000 person-years of hospital contacts with selected diagnoses among 12-15 year old girls (red line) and 12-15 year old boys (blue line). Black line shows annual coverage of HPV vaccination in girls.




TABLE 1. Characteristics of HPV vaccinated and non-vaccinated girls at age 11 years and their parents

	HPV non-vaccinated girls (N=44,038)	HPV vaccinated girls (N=184,597)
Girls at age 11 years:		
Asthma	5.6%	5.2%
Previous severe infection	8.2%	8.0%
Mental disorder	6.9%	5.5%
Diabetes	0.33%	0.26%
Previous psychologist or psychiatrist visit	1.2%	1.0%
>25 previous GP contacts	52.7%	49.6%
Parents of the girls:		
Higher education (university)	17.6%	15.1%
Both parents employed	62.5%	71.7%
Annual income of parents >490,000 DKR (>65,700 EUR)	69.8%	75.9%
Parents = married	62.8%	66.4%
Non-Danish ethnicity	13.8%	9.9%

TABLE 2. Incidence rates and adjusted incidence rate ratios of hospital contacts with selected diagnoses in girls exposed versus non-exposed to HPV vaccination

Outcome	HPV vaccine non-exposed		HPV vaccine exposed		Crude IRR (95% CI)	Adjusted* IRR (95% CI)
	n	Incidence rate /1,000 pyts	n	Incidence rate /1,000 pyts		
Abdominal Pain	2772	8.21	6423	10.36	1.07 (1.02-1.13)	1.08 (1.03-1.14)
Unspecific pain	337	0.95	920	1.39	1.18 (1.03-1.35)	1.26 (1.08-1.46)
Headache	513	1.45	1352	2.05	1.25 (1.12-1.40)	1.36 (1.21-1.54)
Hypotension/syncope	725	2.05	2458	3.75	1.42 (1.29-1.55)	1.39 (1.26-1.53)
Tachycardia	108	0.30	429	0.65	1.60 (1.28-2.02)	1.59 (1.24-2.04)
Malaise/fatigue	106	0.30	506	0.75	1.56 (1.24-1.95)	1.60 (1.25-2.04)
Chronic fatigue syndrome	11	0.03	6	0.01	0.17 (0.06-0.49)	0.20 (0.06-0.62)
Trauma	12330	92.4	14996	75.6	0.84 (0.92-0.95)	0.89 (0.87-0.92)
Diabetes	166	0.47	233	0.35	0.89 (0.72-1.11)	0.88 (0.70-1.10)
Cancer	41	0.12	86	0.13	1.00 (0.67-1.51)	0.94 (0.61-1.44)
Pneumonia	194	0.57	411	0.65	0.83 (0.69-1.01)	0.82 (0.67-1.00)
Asthma	577	1.72	1047	1.67	1.00 (0.89-1.12)	0.92 (0.82-1.04)
Appendicitis	583	1.94	1374	2.10	1.05 (0.95-1.16)	0.96 (0.86-1.07)

*Adjusted by Cox regression for year of entry (2008-2014), history of asthma, diabetes, infections, or mental disorders, frequency of GP contacts, previous psychiatric tests or talk therapy, of GPs, previous psychologist or psychiatrist visit, education of parents (primary, secondary, higher), employment of parents (none, one, both), income of parents in DKR (<-490,000, 490,000-650,000, 650,000-840,000, >840,000), marital status of parents (married, other), and ethnicity (non-Danish, Danish)

CONCLUSION

We found increased rates of a number of unspecific diagnoses in HPV-vaccinated vs. unvaccinated girls, but no increase on the population level after vaccine introduction. It is unclear if our results reflect causal vaccine effects, differences in care seeking, or lack of knowledge about diagnostic specificity, coding practice, and etiological window.

CV

Personal data

Name: Jesper Mehlsen. Date of birth: 26-06-1952. Home address: Folkets Alle 2, DK-2000 Frederiksberg

Education/academic degrees

1979 MD, University of Copenhagen. 1990 Specialist in Clinical Physiology & Nuclear Medicine

Recent positions

2019 - Senior Researcher, Section of Surgical Pathophysiology, Rigshospitalet (National Hospital), University of Copenhagen
2019- Private Practice, Diakonissestiftelsen, Frederiksberg – home page: klinikmehlsen.com (Danish)
2016-2019 Senior Consultant, Syncope Centre, Department of Cardiology, Bispebjerg & Frederiksberg Hospitals
2010-2016 Director of Research, Coordinating Research Centre, Frederiksberg Hospital, University of Copenhagen

Previous clinical positions in the following medical specialties:
Neurology, Endocrinology, Rheumatology, Urology.

National and International collaboration

Dept. Neuro-anesthesiology, Rigshospitalet, University of Copenhagen – collaboration with prof. Kirsten Møller on autonomic dysfunction in patients with traumatic brain injury.
Institute of Mathematics, North Carolina State University – collaboration with prof Mette Olufsen on mathematical models of autonomic cardiovascular control.
Dept. of Science, Systems, and Models, Roskilde University – collaboration with prof Johnny T Ottesen on mathematical modelling of cardiovascular control
Max-Delbrück-Centrum für Molekuläre Medizin, Berlin – collaboration with ass. prof. Gerd Wallukat on antibodies against receptors in the autonomic nervous system

Supervision of Student (Master, PhD and Postdocs)

Supervisor for Postdocs, Ph.D.-students and medical students on scholarships in Denmark (University of Copenhagen) and USA (North Carolina State University).
Supervisor for Master students at Technical University of Denmark and at Roskilde University Centre.

Experience in management of clinical studies

Member of the International Steering Committee and Danish Principal Investigator for the Anglo-Scandinavian. Clinical Outcomes Trial (ASCOT), a Phase IV GCP-study in hypertensive patients.
Head of the Steering Committee and Principal Investigator in GEPARD, a Phase IV non-interventional trial in peripheral arterial disease.
Head of the Steering Committee and Principal Investigator in PAPAGENO, a Phase IV non-interventional trial in prevention of cardiovascular disease.
Principal Investigator in Parallel, a phase III GCP-trial testing a triple combination of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide in subjects with hypertension.
Principal Investigator in V501-01- follow-up, V503-001, V503-003, V503-006, V503-007, V503-010, all phase III-trials in vaccination with Gardasil 4 or 9 against HPV including a total of 3,200 participants at our centre.
National Coordinator in V503-003 a phase III-trial in vaccination against HPV.

Data on publications

Peer-reviewed scientific articles: 175.
Google Scholar, Juni 2023: Total publications: 332. H-index: 51. Sum of citations: 20,384.

Publications relevant to ME/CFS

- 1.
- 2.
- 3.
4. J Mehlsen, L Brinth, K Pors, K Varming, G Wallukat, RKJ Olsen. Autoimmunity in patients reporting long-term complications after exposure to human papilloma virus vaccination. *J Autoimmunity* 2022 133, 102921
5. P Fernandez-Guerra, AC Gonzalez-Ebsen, SE Boonen, J Courraud, et al. Bioenergetic and proteomic profiling of immune cells in myalgic encephalomyelitis/chronic fatigue syndrome patients: an exploratory study. *Biomolecules* 2021 11 (7), 961
6. J Geddes, J Mehlsen, MS Olufsen. Characterization of blood pressure and heart rate oscillations of POTS patients via uniform phase empirical mode decomposition. *IEEE Transactions on Biomedical Engineering* 67 (11), 3016-3025
7. Brinth, H Nielsen, K Varming, SE Boonen, et al. Myalgisk encefalomyelitis eller kronisk træthedssyndrom *Ugeskr Læger* 2020 181, V0818050 (Danish)
8. J Campbell-Tofte, A Vrahatis, K Josefsen, J Mehlsen, K Winther. Investigating the aetiology of adverse events following HPV vaccination with systems vaccinology. *Cellular and molecular life sciences* 2020 76, 67-87

Latest 10 publications not related to ME/CFS

1. MN Frandsen, C Varnum, NB Foss, J Mehlsen, H Kehlet. Time-course of heart rate variability after total hip arthroplasty. *J Clin Monit Comput* 2024 38 (2), 423-432
2. KA. Seton, J Espejo-Oltra, K Giménez-Orenga, R Haagmans, D J. Ramadan, R Torok, J Mehlsen. Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives on behalf of the European ME Research Group for Early Career Researchers (Young EMERG). *J Clin Med.* 38:423-32. 2024
3. LS Brinth, T Jørgensen, J Mehlsen, MW Petersen, L Gormsen, et al. Normative values of short-term heart rate variability in a cross-sectional study of a Danish population. *The DanFunD study. Scan J of Public Health* 52 (1), 48-57. 2024
4. M Damkjær, SA Simonsen, AV Heiberg, J Mehlsen, AS West, P Jennum, et al. Autonomic dysfunction after mild acute ischemic stroke and six months after: a prospective observational cohort study. *BMC neurology* 2023 23 (1), 1-11
5. MN Frandsen, L Huang, RH Petersen, NB Foss, J Mehlsen, H Kehlet Continuous perioperative heart rate variability monitoring in video-assisted thoracoscopic surgery lobectomy—a pilot study. *Journal of Clinical Monitoring and Computing*, 2023, 1-9.
6. CB Nordsten, CR Molbech, J Mehlsen, TL Sørensen Heart-Rate Variability Correlates to Choroidal Thickness in Central Serous Chorioretinopathy. *Clinical Ophthalmology*, 2443-2447.2023
7. MN Frandsen, C Varnum, NB Foss, J Mehlsen, H Kehlet Time-course of heart rate variability after total hip arthroplasty. *Journal of Clinical Monitoring and Computing*, 1-10. 2023
8. MN Frandsen, J Mehlsen, NB Foss, H Kehlet. Pre-operative autonomic nervous system function—a missing link for post-induction hypotension? *Anaesthesia* 77 (2), 139-142
9. MH Olsen, CG Riberholt, J Mehlsen, RMG Berg, K Møller. Reliability and validity of the mean flow index (Mx) for assessing cerebral autoregulation in humans: a systematic review of the methodology. *Journal of Cerebral Blood Flow & Metabolism* 42 (1), 27-38
10. CG Riberholt, MH Olsen, CB Søndergaard, C Gluud, C Ovesen, et al. Early orthostatic exercise by head-up tilt with stepping vs. standard care after severe. traumatic brain injury is feasible. *Frontiers in neurology* 12, 626014.

Ful list of publication according to Google Scholar:

[Time-course of heart rate variability after total hip arthroplasty](#)

MN Frandsen, C Varnum, NB Foss, J Mehlsen, H Kehlet
Journal of Clinical Monitoring and Computing 38 (2), 423-432

202

[Normative values of short-term heart rate variability in a cross-sectional study of a Danish population. The DanFunD study](#)

LS Brinth, T Jørgensen, J Mehlsen, MW Petersen, L Gormsen, ...
Scandinavian Journal of Public Health 52 (1), 48-57

4

[Advancing research and treatment: an overview of clinical trials in myalgic encephalomyelitis/chronic fatigue syndrome \(ME/CFS\) and future perspectives](#)

KA Seton, JA Espejo-Oltra, K Giménez-Orenga, R Haagmans, ...
Journal of Clinical Medicine 13 (2), 325

4

[Heart-Rate Variability Correlates to Choroidal Thickness in Central Serous Chorioretinopathy](#)

CB Nordsten, CR Molbech, J Mehlsen, TL Sørensen
Clinical Ophthalmology, 2443-2447

1

[Orthostatic intolerance after acute mild hypovolemia: incidence, pathophysiologic hemodynamics, and heart-rate variability analysis—a prospective observational cohort study](#)

AM Hristovska, B Uldall-Hansen, J Mehlsen, LB Andersen, H Kehlet, ...
Canadian Journal of Anesthesia/Journal canadien d'anesthésie 70 (10), 1587-1599

4

[Continuous perioperative heart rate variability monitoring in video-assisted thoracoscopic surgery lobectomy—a pilot study](#)

MN Frandsen, L Huang, RH Petersen, NB Foss, J Mehlsen, H Kehlet
Journal of Clinical Monitoring and Computing 37 (4), 1071-1079

3

[Autonomic response to early head-up tilt in patients with severe traumatic brain injury: Analysis from a randomized feasibility trial](#)

MD Schultz, M Alstrup, MH Olsen, RMG Berg, J Mehlsen, K Møller, ...
Physiological reports 11 (8), e15666

5

[Orthostatic intolerance after intravenous administration of morphine: incidence, haemodynamics and heart rate variability analysis.](#)

AM Hristovska, B Uldall-Hansen, J Mehlsen, H Kehlet, NB Foss
Anaesthesia 78 (4)

1

[Autonomic dysfunction after mild acute ischemic stroke and six months after: a prospective observational cohort study](#)

7

M Damkjær, SA Simonsen, AV Heiberg, J Mehlsen, AS West, P Jennum, ...
BMC neurology 23 (1), 26

[Autoimmunity in patients reporting long-term complications after exposure to human papilloma virus vaccination](#) 3

J Mehlsen, L Brinth, K Pors, K Varming, G Wallukat, RKJ Olsen
Journal of Autoimmunity 133, 102921

[Heart rate variability after video-assisted thoracoscopic surgery lobectomy](#)

MN Frandsen, L Huang, RH Petersen, NB Foss, J Mehlsen, H Kehlet

[Orthostatic intolerance after fast-track knee arthroplasty: Incidence and hemodynamic pathophysiology](#) 2

AM Hristovska, LB Andersen, M Grentoft, J Mehlsen, K Gromov, H Kehlet, ...
Acta Anaesthesiologica Scandinavica 66 (8), 934-943

[Postural orthostatic tachycardia syndrome explained using a baroreflex response model](#) 2

JR Geddes, JT Ottesen, J Mehlsen, MS Olufsen
Journal of the Royal Society Interface 19 (193), 20220220

[Preoperative heart rate variability as a predictor of perioperative outcomes: a systematic review without meta-analysis](#) 19

MN Frandsen, J Mehlsen, NB Foss, H Kehlet
Journal of Clinical Monitoring and Computing 36 (4), 947-960

[Genetic association study in myalgic encephalomyelitis/chronic fatigue syndrome \(ME/CFS\) identifies several potential risk loci](#) 14

R Hajdarevic, A Lande, J Mehlsen, A Rydland, DD Sosa, EB Strand, ...
Brain, Behavior, and Immunity 102, 362-369

[Derfor har Danmark brug for et nyt videnskabeligt selskab](#)

A Jung, A Frølich, JS Andersen, LK Nielsen, J Mehlsen, CW Appel, ...
Dagens Medicin

[Pre-operative autonomic nervous system function—a missing link for post-induction hypotension?](#) 13

MN Frandsen, J Mehlsen, N Bang Foss, H Kehlet
Anaesthesia 77 (2)

[Reliability and validity of the mean flow index \(Mx\) for assessing cerebral autoregulation in humans: a systematic review of the methodology](#) 23

MH Olsen, CG Riberholt, J Mehlsen, RMG Berg, K Møller
Journal of Cerebral Blood Flow & Metabolism 42 (1), 27-38

- [Statistical analysis plan: Early mobilization by head-up tilt with stepping versus standard care after severe traumatic brain injury](#) [2](#)
CG Riberholt, C Gluud, JC Jakobsen, C Ovesen, J Mehlsen, K Møller
Contemporary Clinical Trials Communications 24, 100856
- [Dynamic cerebral autoregulation during early orthostatic exercise in patients with severe traumatic brain injury: further exploratory analyses from a randomized clinical ...](#) [7](#)
CG Riberholt, MH Olsen, RMG Berg, J Mehlsen, K Møller
Journal of Clinical Neuroscience 92, 39-44
- [Bioenergetic and proteomic profiling of immune cells in myalgic encephalomyelitis/chronic fatigue syndrome patients: an exploratory study](#) [15](#)
P Fernandez-Guerra, AC Gonzalez-Ebsen, SE Boonen, J Courraud, ...
Biomolecules 11 (7), 961
- [Early orthostatic exercise by head-up tilt with stepping vs. standard care after severe traumatic brain injury is feasible](#) [13](#)
CG Riberholt, MH Olsen, CB Søndergaard, C Gluud, C Ovesen, ...
Frontiers in neurology 12, 626014
- [Classification of orthostatic intolerance through data analytics](#) [3](#)
S Gilmore, J Hart, J Geddes, CH Olsen, J Mehlsen, P Gremaud, ...
Medical & Biological Engineering & Computing 59, 621-632
- [Reliability of the transcranial Doppler ultrasound-derived mean flow index for assessing dynamic cerebral autoregulation in healthy volunteers](#) [8](#)
CG Riberholt, MH Olsen, LT Skovgaard, RMG Berg, K Møller, J Mehlsen
Medical Engineering & Physics 89, 1-6
- [A physiological model of the inflammatory-thermal-pain-cardiovascular interactions during an endotoxin challenge](#) [9](#)
A Dobrev, R Brady-Nicholls, K Larripa, C Puelz, J Mehlsen, MS Olufsen
The Journal of physiology 599 (5), 1459-1485
- [Translation and linguistic validation of the Composite Autonomic Symptom Score COMPASS 31 in Danish](#) [10](#)
L Brinth, K Pors, J Mehlsen, DM Sletten, AJ Terkelsen, W Singer
Dan Med J 69 (3), A07210576
- [Early head-up mobilisation versus standard care for patients with severe acquired brain injury: a systematic review with meta-analysis and Trial Sequential Analysis](#) [20](#)

CG Riberholt, V Wagner, J Lindschou, C Gluud, J
Mehlsen, K Møller
PLoS One 15 (8), e0237136

[Characterization of blood pressure and heart rate oscillations of POTS patients via uniform phase empirical mode decomposition](#) [10](#)

J Geddes, J Mehlsen, MS Olufsen
IEEE Transactions on Biomedical Engineering 67 (11),
3016-3025

[Age-related macular degeneration and the inflammatory reflex](#)

CR Molbech, J Mehlsen, TL Sørensen
University of Copenhagen, Faculty of Health and Medical
Sciences

[A model-based analysis of autonomic nervous function in response to the Valsalva maneuver](#) [21](#)

EB Randall, A Billeschou, LS Brinth, J Mehlsen, MS
Olufsen
Journal of Applied Physiology 127 (5), 1386-1402

[Cardiovascular dynamics during head-up tilt assessed via pulsatile and non-pulsatile models](#) [15*](#)

ND Williams, R Brady, S Gilmore, P Gremaud, HT Tran,
JT Ottesen, ...
Journal of mathematical biology 79, 987-1014

[A physiological model of the inflammatory-thermal-pain-cardiovascular interactions during a pathogen challenge](#)

A Dobrev, R Brady, K Larripa, C Puelz, J Mehlsen, MS
Olufsen
arXiv preprint arXiv:1908.07611

[Myalgisk encefalomyelitis eller kronisk træthedssyndrom](#) [1](#)

L Brinth, H Nielsen, K Varming, SE Boonen, AG Ebsen,
...
Ugeskr Læger 181, V08180570

[Myalgic encephalomyelitis or chronic fatigue syndrome](#) [5](#)

L Brinth, H Nielsen, K Varming, SE Boonen, ACG
Ebsen, ...
Ugeskrift for læger 181 (24), V08180570-V08180570

[An optimal control approach for blood pressure regulation during head-up tilt](#) [11](#)

ND Williams, J Mehlsen, HT Tran, MS Olufsen
Biological cybernetics 113 (1), 149-159

[Investigating the aetiology of adverse events following HPV vaccination with systems vaccinology](#) [9](#)

J Campbell-Tofte, A Vrahatis, K Josefsen, J Mehlsen, K
Winther
Cellular and molecular life sciences 76, 67-87

[Early mobilisation by head-up tilt with stepping versus standard care after severe traumatic brain injury–Protocol for a randomised clinical feasibility trial](#) [11](#)

CG Riberholt, J Lindschou, C Gluud, J Mehlsen, K Møller
Trials 19, 1-9

[Type 1 narcolepsy is not present in 29 HPV-vaccinated individuals with subjective sleep complaints](#) 2

EW Torstensen, LS Brinth, J Mehlsen, BR Kornum, PJ Jennum
Dan Med J 65 (11), A5510

[Postural Orthostatic Tachycardia Syndrome \(POTS\) in Denmark: increasingly recognized or new epidemic?](#) 13

L Brinth, K Pors, JM Spahic, R Sutton, A Fedorowski, J Mehlsen
Autonomic Neuroscience 213, 92-95

[Sphenopalatine ganglion stimulation induces changes in cardiac autonomic regulation in cluster headache](#) 14

M Barloese, AS Petersen, S Guo, M Ashina, J Mehlsen, RH Jensen
Clinical Physiology and Functional Imaging 38 (5), 808-815

[Postural orthostatic tachycardia syndrome](#)

LS Brinth, K Pors, J Mehlsen
Ugeskrift for Laeger 180 (27), V12170958-V12170958

[Semen quality associated with subsequent hospitalizations–Can the effect be explained by socio-economic status and lifestyle factors?](#) 30

T Latif, R Lindahl-Jacobsen, J Mehlsen, ML Eisenberg, SA Holmboe, ...
Andrology 6 (3), 428-435

[Effects of increasing the protein intake on physical function and bone health in elderly people with osteopenia.](#)

JL Mehlsen

[Intravenous saline administration in patients with severe acquired brain injury and orthostatic intolerance for tilt-table mobilization](#) 2

C Riberholt, N Olesen, P Hovind, J Mehlsen, TH Petersen
Brain Injury 32 (2), 252-256

[Early trial shows pembrolizumab is effective against rare pregnancy-associated cancer](#)

J Mehlsen, A Chatterjee, OE Iversen, A Joshi, JL Chu, AL Krick, A Saah, ...
peds 2016, 3947

[Personalized mathematical model of endotoxin-induced inflammatory responses in young men and associated changes in heart rate variability](#) 13

R Brady, DO Frank-Ito, HT Tran, S Janum, K Møller, S Brix, JT Ottesen, ...
Mathematical Modelling of Natural Phenomena 13 (5), 42

[4-valent human papillomavirus \(4vHPV\) vaccine in preadolescents and adolescents after 10 years](#) 74

DG Ferris, R Samakoses, SL Block, E Lazcano-Ponce, JA Restrepo, ...
Pediatrics 140 (6)

[Semen quality as a predictor of subsequent morbidity: a Danish cohort study of 4,712 men with long-term follow-up](#) 150

T Latif, T Kold Jensen, J Mehlsen, SA Holmboe, L Brinth, K Pors, ...
American journal of epidemiology 186 (8), 910-917

[Psychiatric conditions and general practitioner attendance prior to HPV vaccination and the risk of referral to a specialized hospital setting because of suspected adverse ...](#) 19

TH Lützen, BH Bech, J Mehlsen, C Høstrup Vestergaard, LW Krogsgaard, ...
Clinical epidemiology, 465-473

[A new wavelet-based ECG delineator for the evaluation of the ventricular innervation](#) 33

M Cesari, J Mehlsen, AB Mehlsen, HBD Sorensen
IEEE journal of translational engineering in health and medicine 5, 1-15

[Integrated inflammatory stress \(ITIS\) model](#) 21

EO Bangsgaard, PG Hjorth, MS Olufsen, J Mehlsen, JT Ottesen
Bulletin of Mathematical Biology 79, 1487-1509

[MRI findings in patients with acute optic neuritis. A prospective study](#)

K Soelberg, P Skejød, J Mehlsen, J Grauslund, F Paul, T Smith, S Lillevang, ...
Investigative Ophthalmology & Visual Science 58 (8), 4842-4842

[The Danish study of Functional Disorders \(DanFunD\)-A Cohort Presentation](#)

T Dantoft, P Fink, LF Eplov, S Skovbjerg, J Mehlsen, A Linneberg, ...
Journal of Psychosomatic Research 97, 143

[Cohort description: the Danish study of functional disorders](#) 84

TM Dantoft, JF Ebstrup, A Linneberg, S Skovbjerg, AL Madsen, J Mehlsen, ...
Clinical Epidemiology, 127-139

[Association between use of cannabis in adolescence and weight change into midlife](#) 40

LZ Jin, A Rangan, J Mehlsen, LB Andersen, SC Larsen, BL Heitmann
PloS one 12 (1), e0168897

[Clinical Epidemiology Dove press](#)

TH Lützen, BH Bech, J Mehlsen, CH Vestergaard, LW Krogsgaard, ...
Clinical Epidemiology 9, 465-473

[Association Between Use of Cannabis in Adolescence and Weight Change into Midlife](#)

BL Heitmann, L Jin, A Rangan, LB Andersen, SC Larsen, J Mehlsen
Public Library of Science

[Effect of Leucine-Rich Whey Protein as Compared to Soy Protein on Muscle Function in Elderly Individuals with Osteopenia. A Four Month Randomized Study](#) 1

JL Mehlsen, SB Pedersen, KI Nørgaard, BL Langdahl, N Møller, ...
Journal of Aging Research and Clinical Practice 6, 200-209

[A COHORT PRESENTATION OF THE DANISH STUDY OF FUNCTIONAL DISORDERS \(DANFUND\)](#)

T Jorgensen, TM Dantoft, LF Epløv, S Skovbjerg, J Mehlsen, A Linneberg, ...
INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE 23, S222-S223

[Pain perception in healthy volunteers: effect of repeated exposure to experimental systemic inflammation](#) 23

S Janum, ST Nielsen, MU Werner, J Mehlsen, H Kehlet, K Møller
Innate Immunity 22 (7), 546-556

[Signal abnormalities on magnetic resonance imaging in acute optic neuritis. A prospective study](#)

K Soelberg, HPB Skejoe, J Mehlsen, J Grauslund, F Paul, TJ Smith, ...

[Classification of syncope through data analytics](#) 2

J Hart, J Mehlsen, CH Olsen, MS Olufsen, P Gremaud
arXiv preprint arXiv:1609.02049

[Personalized mathematical model predicting endotoxin-induced inflammatory responses in young men](#) 5

R Brady, DO Frank-Ito, HT Tran, S Janum, K Møller, S Brix, JT Ottesen, ...
arXiv preprint arXiv:1609.01570

[Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing Response](#)

LS Brinth, J Mehlsen
VACCINE 34 (38), 4469-4469

[Application of a new robust ECG T-wave delineation algorithm for the evaluation of the autonomic innervation of the myocardium](#) 6

M Cesari, J Mehlsen, AB Mehlsen, HBD Sorensen
2016 38th Annual International Conference of the IEEE Engineering in ...

[Is HPV \(human papilloma virus\) vaccine associated with later onset of narcolepsy type 1?](#)

EW Torstensen, LS Brinth, J Mehlsen, PJ Jennum
EUROPEAN JOURNAL OF NEUROLOGY 23, 239-239

[CEREBRAL AUTOREGULATION IN PATIENTS WITH SEVERE BRAIN INJURY](#)

CG Riberholt, ND Olesen, M Thing, TH Petersen, J Mehlsen
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 36, 535-535

[Impaired cerebral autoregulation during upright tilt in patients with severe brain injury](#)

CR Hansen, N Olesen, M Thing, CB Juhl, J Mehlsen, TH Petersen

[Impaired cerebral autoregulation during head up tilt in patients with severe brain injury](#)

30

CG Riberholt, ND Olesen, M Thing, CB Juhl, J Mehlsen, TH Petersen
PLoS One 11 (5), e0154831

[of host publication: Proceedings of 38th Annual International Conference of the IEEE Engineering in Medicine and](#)

M Cesari, J Mehlsen, A Mehlsen, HBD Sørensen
IEEE

[Extracellular vesicles as potential biomarkers in female patients with suspected adverse effects to the quadrivalent Human Papilloma Virus vaccine](#)

R Bæk, MM Jørgensen, LS Brinth, J Mehlsen, K Varming
15th Human Proteome Organization World Congress
September 18-22, 2016 Taipei ...

[Impaired cerebral autoregulation during upright tilt in patients with severe brain injury](#)

C Riberholt, N Olesen, M Thing, CB Juhl, J Mehlsen, TH Petersen
BRAIN INJURY 30 (5-6), 661-661

[Oral midodrine hydrochloride for prevention of orthostatic hypotension during early mobilization after hip arthroplasty: a randomized, double-blind, placebo-controlled trial](#)

48

Ø Jans, J Mehlsen, P Kjærsgaard-Andersen, H Husted, S Solgaard, ...
Anesthesiology 123 (6), 1292-1300

[Decreased heart rate variability responses during early postoperative mobilization—an observational study](#)

25

Ø Jans, L Brinth, H Kehlet, J Mehlsen
BMC anesthesiology 15, 1-9

[Blunted autonomic response in cluster headache patients](#)

13

M Barloese, L Brinth, J Mehlsen, P Jennum, HIS Lundberg, R Jensen
Cephalalgia 35 (14), 1269-1277

[Tilt-table testing of patients with pacemaker and recurrent syncope](#)

6

C Haarmark, JK Kanters, J Mehlsen
indian pacing and electrophysiology journal 15 (4), 193-

198

[Is chronic fatigue syndrome/myalgic encephalomyelitis a relevant diagnosis in patients with suspected side effects to human papilloma virus vaccine](#) [35](#)

L Brinth, K Pors, AAG Hoppe, I Badreldin, J Mehlsen
Int J Vaccines Vaccin 1 (1), 00003

[Reduced baroreflex sensitivity in cluster headache patients](#) [9](#)

MCJ Barloese, J Mehlsen, L Brinth, HIS Lundberg, PJ Jennum, ...
Headache: The Journal of Head and Face Pain 55 (6), 815-824

[An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy ...](#) [54](#)

P Kosalaraksa, J Mehlsen, T Vesikari, A Forstén, K Helm, P Van Damme, ...
The Pediatric infectious disease journal 34 (6), 627-634

[Cerebral oxygenation during tilt in severe brain injury](#) [1](#)

CG Riberholt, N Olesen, M Thing, J Mehlsen, TH Petersen

[Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus](#) [143](#)

LS Brinth, K Pors, AC Theibel, J Mehlsen
Vaccine 33 (22), 2602-2605

[Postural ortostatisk takykardi-syndrom](#)

L Brinth, K Pors, J Mehlsen
Ugeskrift for Laeger 177 (18), 853-6

[Postural orthostatic tachycardia syndrome](#) [4*](#)

L Brinth, K Pors, J Mehlsen
Ugeskrift for Laeger 177 (18), 853-856

[Suspected side effects to the quadrivalent human papilloma vaccine](#) [127](#)

L Brinth, AC Theibel, K Pors, J Mehlsen
Dan Med J 62 (4), A5064

[Using Kalman filtering to predict time-varying parameters in a model predicting baroreflex regulation during head-up tilt](#) [17](#)

B Matzuka, J Mehlsen, H Tran, MS Olufsen
IEEE Transactions on Biomedical Engineering 62 (8), 1992-2000

[A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women](#) [1649](#)

EA Joura, AR Giuliano, OE Iversen, C Bouchard, C Mao, J Mehlsen, ...
New England Journal of Medicine 372 (8), 711-723

[Broad Spectrum HPV Vaccine Study](#) [21](#)

EA Joura, AR Giuliano, OE Iversen, C Bouchard, C Mao, J Mehlsen, ...

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in ...

[MON-PP281: Does Quality or Quantity of Protein Impact Physical Performance and Body Composition in Elderly? A Human Clinical Trial](#)

JL Mehlsen, B Richelsen
Clinical Nutrition, S231

[99mTc-DTPA renography before and after SWL](#)

KH Andreassen, K Affeldt, V Kristensen, RB Hansen, ML Møller, ...

[Patient-specific modelling of head-up tilt](#)

ND Williams, O Wind-Willassen, AA Wright, J Mehlsen, JT Ottesen, ...

Mathematical medicine and biology: a journal of the IMA
31 (4), 365-392

[Structural correlation method for model reduction and practical estimation of patient specific parameters illustrated on heart rate regulation](#)

JT Ottesen, J Mehlsen, MS Olufsen
Mathematical biosciences 257, 50-59

[Long-term study of a quadrivalent human papillomavirus vaccine](#)

D Ferris, R Samakoses, SL Block, E Lazcano-Ponce, JA Restrepo, ...

Pediatrics 134 (3), e657-e665

[ASCOT Trial](#)

J Mehlsen
Methods and Applications of Statistics in Clinical Trials: Concepts ...

[Comparative study of T-amplitude features for fitness monitoring using the ePatch® ECG recorder](#)

JR Thorpe, T Saida, J Mehlsen, AB Mehlsen, H Langberg, K Hoppe, ...

2014 36th Annual International Conference of the IEEE
Engineering in ...

[Postural orthostatic tachycardia syndrome](#)

L Brinth, K Pors, J Mehlsen

Ugeskrift for Laeger 176 (11B), V09130555-V09130555

[Carotid sinus syndrome and cardiovagal regulation in elderly patients with suspected syncope-related falls](#)

L Brinth, T Latif, K Pors, A Kjær, J Mehlsen

Healthy Aging Research 3 (6), 1-9

[Hypertension: Open Access](#)

L Brinth, K Pors, T Latif, A Kjær, J Mehlsen

[Interarm difference in blood pressure: reproducibility and association with peripheral vascular disease](#)

- J Mehlsen, N Wiinberg
International journal of vascular medicine 2014 (1),
841542
- [Reduced sympathetic activity in idiopathic rapid-eye-movement sleep behavior disorder and Parkinson's disease](#) 59
GL Sorensen, J Mehlsen, P Jennum
Autonomic Neuroscience 179 (1-2), 138-141
- [Patients with severe acquired brain injury show increased arousal in tilt-table training](#) 46
CG Riberholt, JB Thorlund, J Mehlsen, AM Nordenbo
Dan Med J 60 (12), A4739
- [Genetic variation in the parasympathetic signaling pathway in patients with reflex syncope](#) 9
HN Holmegard, M Benn, J Mehlsen, S Haunsø
Genet. Mol. Res 12 (3), 2601-2610
- [External pneumatic compression device prevents fainting in standing weight-bearing MRI: a cohort study](#) 15
BB Hansen, R Bouert, H Bliddal, R Christensen, T Bendix, A Christensen, ...
Skeletal radiology 42, 1437-1442
- [Differential effects of endurance training and weight loss on plasma adiponectin multimers and adipose tissue macrophages in younger, moderately overweight men](#) 68
P Auerbach, P Nordby, LQ Bendtsen, JL Mehlsen, SK Basnet, ...
American Journal of Physiology-Regulatory, Integrative and Comparative ...
- [Prevalence of family history in patients with reflex syncope](#) 12
HN Holmegard, M Benn, M Kaijer, S Haunsø, J Mehlsen
Journal of Clinical Neuroscience 20 (5), 692-696
- [External pneumatic compression device prevents fainting in standing weight-bearing magnetic resonance imaging: a cohort study](#)
BB Hansen, R Bouert, H Bliddal, R Christensen, T Bendix, A Christensen, ...
European Congress of Radiology-ECR 2013
- [Tilt-table training in patients with severe acquired brain injury admitted for sub-acute rehabilitation-A feasibility study.](#)
CG Riberholt, JB Thorlund, J Mehlsen, AM Nordenbo
- [ESWL treatment of solitary renal calculi, results 1 month post treatment](#)
RB Hansen, ML Møller, J Mehlsen, V Kristensen, KH Andreassen
Scandinavian Journal of Urology and Nephrology 47, 20
- [Changes in renography before and after ESWL](#)
RB Hansen, ML Møller, J Mehlsen, K Affeldt, V Kristensen, ...

[Predictors of clinically significant decrease in GFR following ESWL](#)

RB Hansen, ML Møller, J Mehlsen, K Affeldt, V Kristensen, ...
Scandinavian Journal of Urology and Nephrology

[Results one month after ESWL of solitary renal calculi](#)

RB Hansen, ML Møller, J Mehlsen, J Affeldt, V Kristensen, ...

[Challenges in practical computation of global sensitivities with application to a baroreceptor reflex model](#)

CH Olsen, HT Tran, JT Ottesen, J Mehlsen, MS Olufsen
North Carolina State University. Center for Research in Scientific Computation

[E72 Renographic changes after ESWL of solitary renal calculi](#)

RB Hansen, ML Møller, J Mehlsen, K Affeldt, V Kristensen, ...
European Urology Supplements 3 (12), 55

[Differences in autonomic balance in patients with cardioinhibitory and vasodepressor type of reflex syncope during head-up tilt test and active standing](#)

HN Holmegard, M Benn, M Kaijer, S Haunsø, J Mehlsen
Scandinavian Journal of Clinical and Laboratory Investigation 72 (4), 265-273

[Autonomic nervous instability in postoperative orthostatic intolerance after hip arthroplasty: 4AP8-2](#)

O Jans, J Mehlsen, L Brinth, H Kehlet
European Journal of Anaesthesiology| EJA 29, 73

[Individualized optimization of the screening interval for diabetic retinopathy: a new model](#)

J Mehlsen, M Erlandsen, PL Poulsen, T Bek
Acta ophthalmologica 90 (2), 109-114

[Global sensitivity and identifiability analysis applied to a model predicting baroreflex regulation during head-up tilt](#)

J Mehlsen, JT Ottesen, H Tran, M Olufsen
Proceeding of The 1st international workshop on innovative simulation for ...

[Is asystole during tilt testing association with significant arrhythmia?](#)

J Mehlsen, L Brinth, AB Mehlsen
FUNDAMENTAL & CLINICAL PHARMACOLOGY 25 (6), II-III

[Lack of effect of short-term treatment with amlodipine and lisinopril on retinal autoregulation in normotensive patients with type 1 diabetes and mild diabetic retinopathy](#)

J Mehlsen, P Jeppesen, M Erlandsen, PL Poulsen, T Bek
Acta Ophthalmologica 89 (8), 764-768

[Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy](#)

T Aspelund, Ó Þórisdóttir, E Olafsdóttir, A
Gudmundsdóttir, AB Einarisdóttir, ...
Diabetologia 54, 2525-2532

[Differences in autonomic balance in patients with
cardioinhibitory and vasodepressor type of reflex syncope
during head-up tilt test and active standing](#)

HN Holmegard, M Benn, M Kaijer, S Haunsø, J Mehlsen
Autonomic Neuroscience: Basic and Clinical 163 (1), 100

[Identification of independent risk factors for the
development of diabetic retinopathy requiring treatment](#) 55

J Mehlsen, M Erlandsen, PL Poulsen, T Bek
Acta ophthalmologica 89 (6), 515-521

[The impact of gravity during head-up tilt](#) 4

MS Olufsen, B Smith, J Mehlsen, J Ottesen
2011 Annual International Conference of the IEEE
Engineering in Medicine and ...

[Decreased heart rate variability in HIV positive patients
receiving antiretroviral therapy: importance of blood
glucose and cholesterol](#) 37

G Askgaard, US Kristoffersen, J Mehlsen, G Kronborg, A
Kjaer, ...
PloS one 6 (5), e20196

[The impact of gravity during head-up tilt](#)

JT Ottesen, M Olufsen, B Smith, J Mehlsen

[High prevalence of peripheral arterial disease in patients
with previous cerebrovascular or coronary event](#) 33

J Mehlsen, N Wiinberg, BS Joergensen, P Schultz-Larsen
Blood Pressure 19 (5), 308-312

[Individualization of screening intervals. Methodology and
practical challenges](#)

T Bek, J Mehlsen
ACTA OPHTHALMOLOGICA 88, 49-49

[Information technology to control screening for diabetic
retinopathy](#) 1

E Stefansson, E Olafsdóttir, A Guðmundsdóttir, T Bek, J
Mehlsen, ...
Investigative Ophthalmology & Visual Science 51 (13),
2092-2092

[P1. 10 Autonomic control of heart rate and blood pressure
in Anderson–Fabry's disease](#)

J Mehlsen, M Ballegaard, U Feldt-Rasmussen, AB
Mehlsen
Autonomic Neuroscience: Basic and Clinical 149 (1), 63

[P2. 5 T-wave amplitude variation as marker of autonomic
nervous control of the heart](#)

AB Mehlsen, J Mehlsen
Autonomic Neuroscience: Basic and Clinical 149 (1), 75

[IDENTIFICATION OF RISK FACTORS FOR THE](#)

[DEVELOPMENT OF DIABETIC RETINOPATHY REQUIRING TREATMENT](#)

J Mehlsen, M Erlandsen, T Bek
EUROPEAN JOURNAL OF OPHTHALMOLOGY 19
(3), 516-516

[Optimizing the Examination Interval During Screening for Diabetic Retinopathy: PhD Dissertation](#)

JMJ Mehlsen
Faculty of Health Sciences, Aarhus University

[Oscillometric blood pressure measurement: a simple method in screening for peripheral arterial disease](#)

35

J Mehlsen, N Wiinberg, C Bruce
Clinical physiology and functional imaging 28 (6), 426-429

[The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes](#)

180

J Östergren, NR Poulter, PS Sever, B Dahlöf, H Wedel, G Beevers, ...
Journal of hypertension 26 (11), 2103-2111

[Hypertension--er det lige meget, hvordan vi saenker blodtrykket?](#)

J Mehlsen
Ugeskrift for Laeger 170 (36), 2782-4

[High prevalence of peripheral arterial disease in patients with previous cerebrovascular or coronary events](#)

J Mehlsen, N Wiinberg, BS Joergensen, P Schultz-Larsen
EUROPEAN HEART JOURNAL 29, 89-89

[Hypertension--does it matter how blood pressure is lowered?](#)

J Mehlsen
Ugeskrift for Laeger 170 (36), 2782-2784

[657 Ventricular tachyarrhythmias are uncommon in stable outpatients with systolic Heart Failure during 48 hours holter monitoring](#)

P Corell, F Gustafsson, J Mehlsen, J Rosenberg, P Hildebrandt
European Journal of Heart Failure Supplements 7, 162-162

[Effect of eight weeks of endurance exercise training on right and left ventricular volume and mass in untrained obese subjects: a longitudinal MRI study](#)

45

TW Vogelsang, B Hanel, US Kristoffersen, CL Petersen, J Mehlsen, ...
Scandinavian journal of medicine & science in sports 18 (3), 354-359

[Changes in the Diameter of Retinal Vessels in vivo After Topical Application of a Prostaglandin Agonist and a Prostaglandin Synthesis Inhibitor: A Pilot Study](#)

JM Mehlsen, KB Tilma, T Bek

Investigative Ophthalmology & Visual Science 49 (13),
940-940

[Udredning og behandling af reflekssynkoper](#)

[1](#)

J Mehlsen, AB Mehlsen
Ugeskrift for Laeger 170 (9), 718-23

[Udredning ved mistanke om synkope](#)

A Mehlsen, J Mehlsen
Ugeskrift for Laeger 170 (9), 723

[Diabetes og hypertension. Resultater fra ADVANCE-studiet](#)

J Mehlsen
Ugeskrift for Laeger 170 (7), 531-2

[Diagnosis and treatment of syncope](#)

J Mehlsen, AB Mehlsen
Ugeskrift for Laeger 170 (9), 718-723

[Investigation in suspected syncope. A study of more than 1,174 consecutively referred patients](#)

[2](#)

AB Mehlsen, J Mehlsen
Ugeskrift for Laeger 170 (9), 723-727

[The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure](#)

[125](#)

PS Sever, NR Poulter, B Dahlof, H Wedel, G Beevers, M Caulfield, ...
European heart journal 29 (4), 499-508

[Plasma Adiponectin Concentration and Adiponectin Oligomers Associate with Insulin Sensitivity: Effect of Physical Training and Weight Loss in Overweight Sedentary Men](#)

JL Mehlsen
Københavns Universitet, Det Biovidenskabelige Fakultet for Fødevarer ...

[The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Commentary](#)

H HOLDAAS, PS SEVER, G MCLNNES, J MEHLSSEN, MS NIEMINEN, ...
European heart journal 29 (4)

[Paroxysmal atrial fibrillation is uncommon in outpatients with chronic heart failure](#)

[4](#)

P Corell, F Gustafsson, J Mehlsen, J Rosenberg, P Hildebrandt
Scandinavian Cardiovascular Journal 42 (3), 202-207

[Autonomic and electrocardiographic changes in cardioinhibitory syncope](#)

[61](#)

J Mehlsen, MN Kaijer, AB Mehlsen
Europace 10 (1), 91-95

[Autonomic dysfunction in HIV patients on antiretroviral](#)

[65](#)

[therapy: studies of heart rate variability](#)

AM Lebech, US Kristoffersen, J Mehlsen, N Wiinberg, CL Petersen, ...
Clinical physiology and functional imaging 27 (6), 363-367

[Value of I-123-MIBG scintigraphy in classification of severe autonomic neuropathy](#)

A Mehlsen, J Mehlsen, A Kjaer
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 34, S243-S243

[Arrhythmia associated with cardioinhibitory syncope](#)

J Mehlsen, AB Mehlsen
EUROPEAN HEART JOURNAL 28, 644-644

[Evaluation of dyspnoea in a sample of elderly subjects recruited from general practice](#)

53

F Pedersen, J Mehlsen, I Raymond, D Atar, US Skjoldborg, ...
International journal of clinical practice 61 (9), 1481-1491

[Changes in the diameter of retinal vessels in vivo after topical application of a prostaglandin agonist and a prostaglandin synthesis inhibitor. A pilot study](#)

K Tilma, J Mehlsen, T Bek
EUROPEAN JOURNAL OF OPHTHALMOLOGY 17 (3), 481-481

[Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial \(vol 27, pg 2982, 2006\)](#)

P Sever, B Dahlöf, N Poulter, H Wedel, G Beevers, M Caulfield, R Collins, ...
EUROPEAN HEART JOURNAL 28 (1), 142-142

[Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial](#)

235

P Sever, B Dahlöf, N Poulter, H Wedel, G Beevers, M Caulfield, R Collins, ...
European heart journal 27 (24), 2982-2988

[The Anglo-Scandinavian Cardiac Outcomes Trial: Blood pressure-lowering limb \(ASCOT-BPLA\): effects in patients with type 2 diabetes](#)

J Ostergren, P Sever, N Poulter, B Dahlöf, H Wedel, G Beevers, ...

[Prognostic significance of left ventricular filling parameters in subjects with preserved systolic function from the general population](#)

F Pedersen, I Raymond, D Atar, J Mehlsen, P Hildebrandt
EUROPEAN HEART JOURNAL 27, 853-853

[Autonomic dysfunction and impaired cerebral autoregulation in cirrhosis](#)

36

VG Frøkjær, GI Strauss, J Mehlsen, GM Knudsen, V Rasmussen, ...

Clinical Autonomic Research 16, 208-216

[Interaction Between Pressure Autoregulation and Metabolic Autoregulation in Type 2 Diabetic Patients With Minimal Retinopathy](#)

P Jeppesen, J Sanye–Hajari, J Mehlsen, T Bek
Investigative Ophthalmology & Visual Science 47 (13), 482-482

[Examinations of the autonomic nervous system. The Danish Society of Clinical Physiology and Nuclear Medicine](#)

J Mehlsen
Ugeskrift for læger 168 (12), 1227

[Undersøgelser af det autonome nervesystem. Dansk Selskab for Klinisk Fysiologi og Nuklearmedicin](#)

J Mehlsen
Ugeskrift for Læger 168 (12), 1227

[The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia—a double-blind placebo-controlled study](#) 41

C Randsløv, J Mehlsen, CF Thomsen, C Hedman, H Von Fircks, K Winther
Phytomedicine 13 (4), 215-221

[ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial](#) 92

P Sever, B Dahlöf, N Poulter, H Wedel, G Beevers, M Caulfield, R Collins, ...
Eur Heart J 27 (24), 2982-2988

[Isolated systolic hypertension in an elderly Danish population. Prevalence and daytime ambulatory blood pressure](#) 14

U Talleruphuus, LE Bang, N Wiinberg, J Mehlsen, TL Svendsen, ...
Blood pressure 15 (6), 347-353

[Increased intracranial volume in Parkinson's disease](#) 69

K Krabbe, M Karlsborg, A Hansen, L Werdelin, J Mehlsen, HBW Larsson, ...
Journal of the neurological sciences 239 (1), 45-52

[Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the ...](#) 4750

B Dahlöf, PS Sever, NR Poulter, H Wedel, DG Beevers, M Caulfield, ...
The Lancet 366 (9489), 895-906

[Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm ...](#) 560

NR Poulter, H Wedel, B Dahlöf, PS Sever, DG Beevers,

M Caulfield, ...
The Lancet 366 (9489), 907-913

[P-86: Is a difference in arm blood pressure a useable indicator of peripheral arterial disease?](#)

J Mehlsen, C Bruce, N Wiinberg
American Journal of Hypertension 18 (S4), 38A

[P-37: Brachial artery compliance, neurohormones and vascular collagen in hypertension accompanied by left ventricular hypertrophy. A life study](#)

CD Tuxen, N Wiinberg, MH Olsen, K Wachtell, PR Hildebrandt, J Mehlsen
American Journal of Hypertension 18 (S4), 21A

[P-27: Arterial pulse wave reflection during head up tilt and sublingual nitroglycerin](#)

AB Pedersen, J Mehlsen
American Journal of Hypertension 18 (S4), 18A

[P-85: Oscillometric blood pressure measurement: A simple method in screening for peripheral arterial disease](#)

J Mehlsen, N Wiinberg
American Journal of Hypertension 18 (S4), 38A

[P-110: High prevalence of peripheral arterial disease in hypertension](#) 3

N Wiinberg, J Mehlsen
American Journal of Hypertension 18 (S4), 46A

[Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm \(ASCOT-LLA\)](#) 534

PS Sever, NR Poulter, B Dahlöf, H Wedel, R Collins, G Beevers, ...
Diabetes care 28 (5), 1151-1157

[Sunset and sunrise• EDITORIAL](#)

JS Alpert, TAM Haidich Jr, M Lucas, CJ Michet, M Kuwana, H Yasuoka, ...

[Underekstremitetsiskæmi-forebyggelse og behandling](#) 2

TV Schroeder, LB Ebskov, M Egeblad
København:© Den Almindelige Danske Lægeforening, Lægeforeningens forlag ...

[Prevalence of diastolic dysfunction as a possible cause of dyspnea in the elderly](#) 49

F Pedersen, I Raymond, J Mehlsen, D Atar, PR Hildebrandt
The American journal of medicine 118 (1), 25-31

[Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian ...](#) 174

PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ...

Drugs 64, 43-60

[The prognosis of impaired left ventricular systolic function and heart failure in a middle-aged and elderly population in an urban population segment of Copenhagen](#) 9
I Raymond, J Mehlsen, F Pedersen, J Dimsits, J Jacobsen,
...

European Journal of Heart Failure 6 (5), 653-661

[Echocardiographic indices of left ventricular diastolic dysfunction in 647 individuals with preserved left ventricular systolic function](#) 36

F Pedersen, I Raymond, LH Madsen, J Mehlsen, D Atar,
P Hildebrandt

European Journal of Heart Failure 6 (4), 439-447

[P-286: Brachial artery compliance and ambulatory pulse pressure in hypertension accompanied by left ventricular hypertrophy. a life study](#)

C Tuxen, N Wiinberg, PR Hildebrandt, J Mehlsen
American Journal of Hypertension 17 (S1), 136A

[P-463: Prevalence of hypertension in a large syncope population](#)

AB Pedersen, J Mehlsen

American Journal of Hypertension 17 (S1), 202A

[P-460: Which blood pressure value is the better marker of cardiovascular risk in the elderly?](#) 1

J Mehlsen

American Journal of Hypertension 17 (S1), 201A

[P-287: Brachial artery compliance and neurohormones in hypertension accompanied by left ventricular hypertrophy. A life study](#)

C Tuxen, N Wiinberg, PR Hildebrandt, J Mehlsen
American Journal of Hypertension 17 (S1), 136A

[Prevention of coronary and stroke events in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes ...](#)

PS Sever, B Dahlöf, NR Poulter, H Wedel, D Beevers, M Caulfield, ...

Drugs 64, 43-60

[Objektiv rådgivning omkring lægemidler og lægemiddelforskning](#)

J Mehlsen

Ugeskrift for Læger 165 (51), 4980-1; author reply 4981

[Objective counseling concerning drugs and drug research](#)

J Mehlsen

Ugeskrift for læger 165 (51), 4980-4981

[Er thiaziddiuretika bedre end moderne antihypertensiva?](#)

J Mehlsen

Ugeskrift for Læger 165 (23), 2402-2402

[Are thiazide diuretics better than modern antihypertensive agents?](#)

J Mehlsen
Ugeskrift for Laeger 165 (23), 2402-2403

[P-497: Antihypertensive treatment in an elderly Danish population-treatment patterns](#)

U Talleruphuus, LE Bang, N Wiinberg, J Mehlsen, TL Svendsen
American Journal of Hypertension 16 (S1), 218A

[Sympathetic dysfunction of central origin in patients with ALS](#) 35

M Karlsborg, EB Andersen, N Wiinberg, O Gredal, L Jørgensen, ...
European Journal of Neurology 10 (3), 229-234

[Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian ...](#) 5676

PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ...
The Lancet 361 (9364), 1149-1158

[Brachial artery compliance in hypertension: Effect of losartan and atenolol after one-year of treatment—A LIFE substudy](#)

C Tuxen, N Wiinberg, P Hildebrandt, J Mehlsen
Journal of the American College of Cardiology 41 (6S1), 264-264

[Does isolated diastolic dysfunction explain dyspnea in a population with preserved left ventricular systolic function and no signs of lung disease?](#)

F Pedersen, I Raymond, J Mehlsen, D Atar, P Hildebrandt
Journal of the American College of Cardiology 41 (6S1), 172-172

[ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in ...](#) 1

S PS
Lancet 361, 1149-1158

[Findes der en>> kommerciel bias<<?](#)

M Lindberg, J Mehlsen, ML Larsen, HKF Lublin
UGESKRIFT FOR LAEGER 165 (37), 3539-3542

[The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac ...](#) 66

PS Sever, B Dahlof, NR Poulter, H Wedel, G Beevers, M Caulfield, ...
Lancet 361, 1149-1158

[4P-1201 A combination of Japanese ginseng, Ganoderma](#) 5

[lucidum and Trametes versicolor, referred to as the Goino procedure, can lower blood glucose and LDL-cholesterol in ...](#)

K Winther, J Mehlsen, E Rein, A Hansen, T Goino
Atherosclerosis (Supplements)(Component) 2 (4), 339

[Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers](#)

59

J Mehlsen, H Drabaek, N Wiinberg, K Winther
Clinical physiology and functional imaging 22 (6), 375-378

[The occurrence of left ventricular isolated diastolic dysfunction assessed by Doppler-flow derived parameters in 647 individuals aged 50 to 89](#)

F Pedersen, I Raymond, LH Madsen, J Mehlsen, D Atar, P Hildebrandt
EUROPEAN HEART JOURNAL 23, 330-330

[Regulation of cerebral blood flow in patients with autonomic dysfunction and severe postural hypotension](#)

13

B Hesse, J Mehlsen, F Boesen, JF Schmidt, EB Andersen, G Waldemar, ...
Clinical physiology and functional imaging 22 (4), 241-247

[Isolated systolic hypertension in an elderly Danish population. Prevalence and 24-hour ambulatory blood pressure](#)

UT Talleruphuus, LEB Bang, NW Wiinberg, JM Mehlsen, TLS Svendsen, ...
JOURNAL OF HYPERTENSION 20, S254-S254

[Haemodynamic changes following treatment of subclinical and overt hyperthyroidism](#)

164

J Faber, N Wiinberg, S Schifter, J Mehlsen
European journal of endocrinology 145 (4), 391-396

[Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol](#)

27*

PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ...
Journal of human hypertension 15 (1), S11-S12

[Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial](#)

378

PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ...
Journal of hypertension 19 (6), 1139-1147

[A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure ...](#)

27

LJ Petersen, JR Petersen, U Talleruphuus, ML Møller, SD Ladefoged, ...
Clinical nephrology 55 (5), 375-383

[P-30: Screening for peripheral vascular disease with a simple oscillometric blood pressure equipment](#)

N Wiinberg, J Mehlsen

American Journal of Hypertension 14 (S1), 39A

[P-283: Compliance of peripheral conduit arteries is increased in isolated systolic hypertension accompanied by left ventricular hypertrophy, a life-substudy](#)

N Wiinberg, C Tuxen, J Mehlsen, P Hildebrandt

American Journal of Hypertension 14 (S1), 123A

[P-282: Change in compliance of peripheral conduit arteries during treatment of hypertension accompanied by left ventricular hypertrophy, a life-substudy](#)

C Tuxen, N Wiinberg, P Hildebrandt, J Mehlsen

American Journal of Hypertension 14 (S1), 123A

[P-484: Prevalence of isolated systolic hypertension in elderly Danish citizens](#)

J Mehlsen

American Journal of Hypertension 14 (S1), 193A

[Original papers-Therapeutic trials-Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial](#)

PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ...

Journal of Hypertension 19 (6), 1139-1148

[Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial](#)

PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ...

[Peripheral arterial distensibility and central arterial compliance in essential hypertension accompanied by left ventricular hypertrophy, a life-substudy](#)

C Tuxen, N Wiinberg, P Hildebrandt, J Mehlsen, R Devereaux

JOURNAL OF HYPERTENSION 18, S194-S194

[Models of the venous system](#)

J Mehlsen

Mathematical Modelling in Medicine, 109-117

[Relationship between isobaric compliance of conduit arteries and diastolic heart function in essential hypertension accompanied by left ventricular hypertrophy: A LIFE-Substudy](#)

CD Tuxen, N Wiinberg, PR Hildebrandt, J Mehlsen, JE Liu

CIRCULATION 100 (18), 105-106

[Isobaric compliance of conduit arteries in essential hypertension accompanied by ECG-determined left ventricular hypertrophy: A LIFE-substudy](#)

CD Tuxen, N Wiinberg, J Mehlsen, PR Hildebrandt

CIRCULATION 100 (18), 175-175

- [The influence of autonomic nervous dysfunction on cerebral blood flow autoregulation in patients with cirrhosis of the liver.](#)
GI Strauss, J Mehlsen, BA Hansen, FS Larsen, GM Knudsen
HEPATOLOGY 30 (4), 239A-239A
- [Kardial adaptation til fysisk træning--fysiologiske og kliniske aspekter](#) 1
F Gustafsson, J Mehlsen
Ugeskrift for læger 161 (37), 5169-72
- [Cardiac adaptation to physical training--physiological and clinical aspects](#) 4
F Gustafsson, J Mehlsen
Ugeskrift for Laeger 161 (37), 5169-5172
- [Glomerular filtration rate estimated from the uptake phase of 99mTc-DTPA renography in chronic renal failure.](#) 72
LJ Petersen, JR Petersen, U Talleruphuus, ML Møller, SD Ladefoged, ...
Nephrology, dialysis, transplantation: official publication of the European ...
- [Maximal isometric strength of the cervical musculature in 100 healthy volunteers](#) 210
A Jordan, J Mehlsen, PM Bülow, K Østergaard, B Danneskiold-Samsøe
Spine 24 (13), 1343
- [Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.](#) 263
TJ Berg, O Snorgaard, J Faber, PA Torjesen, P Hildebrandt, J Mehlsen, ...
Diabetes care 22 (7), 1186-1190
- [Effect of a new starch-free bread on metabolic control in NIDDM patients.](#) 6
B Stilling, J Mehlsen, O Hamberg, JJ Larsen, NC Gram, S Madsbad
Nutrition, Metabolism, and Cardiovascular Diseases: NMCD 9 (3), 98-101
- [B007: A randomized and double blind comparison of isradipine, spirapril and their combination on decline in renal function in patients with chronic renal failure and hypertension.](#)
LJ Petersen, JR Petersen, U Tallruphuus, ML Møller, SD Ladefoged, ...
American Journal of Hypertension 12 (S4), 103A-103A
- [Central haemodynamics and vasoactive peptides in subclinical hypothyroidism \(SH\)](#)
J Faber, L Petersen, N Wiinberg, J Mehlsen, S Schifter
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION 22, 66-66
- [Pathophysiology/Complications-Serum levels of advanced](#)

[glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes](#)

TJ Berg, O Snorgaard, J Faber, PA Torjesen, P Hildebrandt, J Mehlsen, ...
Diabetes Care 22 (7), 1186-1190

[Vejledende retningslinjer for hjemmeblodtryksmåling](#)

J Mehlsen, N Wiinberg, LE Bang, MW Bentzon, PE Nielsen, HÆ Jensen
Ugeskr Læger 161

[Effects of Ginkgo biloba extract on cognitive function and blood pressure in elderly subjects](#)

KAJ Winther, C Randløv, E Rein, J Mehlsen
Current therapeutic research 59 (12), 881-888

[Isolated systolic Hypertension-Prevalence and 24-hour ambulatory blood pressure in an elderly Danish population](#)

U Talleruphuus, LE Bang, N Wiinberg, J Mehlsen, TL Svendsen
JOURNAL OF HYPERTENSION 16, S200-S200

[Effect of starch-free bread on metabolic control in type 2 diabetes.](#)

B Stilling, J Mehlsen
The Lancet 352 (9125), 369-370

[Hjertefrekvensvariationer til vurdering af det autonome nervesystem. En oversigt](#)

TL Johansen, G Kambskar, J Mehlsen
Ugeskrift for læger 159 (45), 6666-71

[Heart rate variability in evaluation of the autonomic nervous system. A review](#)

TL Johansen, G Kambskar, J Mehlsen
Ugeskrift for læger 159 (45), 6666-6671

[A comparison of physical characteristics between patients seeking treatment for neck pain and age-matched healthy people.](#)

A Jordan, J Mehlsen, K Ostergaard
Journal of manipulative and physiological therapeutics 20 (7), 468-475

[The pulsatility index and the resistive index in renal arteries. Associations with long-term progression in chronic renal failure.](#)

LJ Petersen, JR Petersen, U Talleruphuus, SD Ladefoged, J Mehlsen, ...
Nephrology, dialysis, transplantation: official publication of the European ...

[Diastolic function and arterial compliance are related to duration of IDDM and urinary albumin excretion.](#)

O Snorgaard, J Faber, N Wiinberg, J Mehlsen, TJ Jakobsen, ...
DIABETOLOGIA 40, 1798-1798

- [Muscle strength, working capacity and effort in patients with fibromyalgia.](#) 124
J Nørregaard, PM Bülow, JJ Lykkegaard, J Mehlsen, ...
Scandinavian journal of rehabilitation medicine 29 (2), 97-102
- [E5: Arterial compliance in patients with essential hypertension](#)
MT Andersen, N Wiinberg, C Tuxen, U Talleruphuus, J Mehlsen
American Journal of Hypertension 10 (S2), 44A-44A
- [E6 Is isobar-arterial compliance in IDDM an indicator of cardiovascular disease?](#)
N Wiinberg, O Snorgaard, J Faber, J Mehlsen
American Journal of Hypertension 4 (10), 44A
- [E8 The effect of proximal stenosis on the peripheral arterial compliance](#)
N Wiinberg, MT Andersen, J Mehlsen, C Hædersdal
American Journal of Hypertension 4 (10), 44A
- [E7 Arterial pressure amplification is dependent of the peripheral arterial compliance](#)
C Hædersdal, MT Andersen, J Mehlsen, N Wiinberg
American Journal of Hypertension 4 (10), 44A
- [Vejledende retningslinjer for ambulant døgnblodtryksmåling](#) 5
J Mehlsen, N Wiinberg, LE Bang, S Rasmussen, KW Hansen
Ugeskr Læger 159 (suppl 8), 1-5
- [2-12-24 Russian root \(Siberian ginseng\) improves cognitive functions in middle-aged people, whereas Ginkgo biloba seems effective only in the elderly](#) 18
K Winther, C Ranløv, E Rein, J Mehlsen
Journal of the Neurological Sciences, S90
- [Exercise training in treatment of fibromyalgia](#) 135
J Nørregaard, JJ Lykkegaard, J Mehlsen, B Danneskiold-Samsøe
Journal of Musculoskeletal Pain 5 (1), 71-79
- [Effect of spirapril and hydrochlorothiazide on platelet function and euglobulin clot lysis time in patients with mild hypertension](#) 20
G Gleerup, JR Petersen, J Mehlsen, K Winther
Angiology 47 (10), 951-956
- [Effekten af Ginkgo biloba-ekstrakt hos patienter med claudicatio intermittens](#) 6
H Drabaek, JR Petersen, N Winberg, KF Hansen, J Mehlsen
Ugeskrift for læger 158 (27), 3928-31
- [The effect of Ginkgo biloba extract in patients with intermittent claudication](#) 19
H Drabaek, JR Petersen, N Winberg, KF Hansen, J

Mehlsen

Ugeskrift for Laeger 158 (27), 3928-3931

[ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension](#) [18](#)

JR Petersen, H Drabaek, G Glerup, J Mehlsen, L Juhl Petersen, ...

Angiology 47 (3), 233-240

[The pulsatility index and the resistive index in renal arteries in patients with hypertension and chronic renal failure](#) [137](#)

LJ Petersen, JR Petersen, SD Ladefoged, J Mehlsen, HÆ Jensen

Nephrology Dialysis Transplantation 10 (11), 2060-2064

[The twitch interpolation technique for study of fatigue of human quadriceps muscle](#) [45](#)

PM Bülow, J Jørregaard, J Mehlsen, B Danneskiold-Samsøe

Journal of neuroscience methods 62 (1-2), 103-109

[DOPPLER ULTRASOUND INDEXES IN RENAL-ARTERIES CORRELATE TO LONG-TERM PROGRESSION IN CHRONIC-RENAL-FAILURE](#)

LJ PETERSEN, JR PETERSEN, J MEHLSSEN, SD LADEFOGED, ...

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 6 (3), 399-399

[Der Effekt einer tibetischen Kräutermischung \(Padma 28\) auf die Gehstrecke bei stabiler Claudicatio intermittens](#) [2](#)

J Mehlsen, H Drabaek, JR Petersen, K Winther

Forschende Komplementärmedizin 2 (5), 240-245

[A40 Pulsatility Index In Renal Arteries Indicates Progression In Chronic Renal Failure.](#)

J Mehlsen, LJ Petersen, JR Petersen, SD Ladefoged, HÆ Jensen

American Journal of Hypertension 8 (4_Pt_2), 161A-161A

[Det arterielle blodtrykts afhaengighed af hjertets fyldning ved svaer ortostatisk hypotension](#)

J Mehlsen, C Haedersdal, KH Stokholm

Ugeskrift for Laeger 157 (3), 295-7

[Inhalt· Contents](#)

J Mehlsen, H Drabaek, JR Petersen, K Winther, LL Wen-Xi, K Stampfli, ...

Complementary Medicine Research 2 (5), 229-231

[Dependency of blood pressure upon cardiac filling in patients with severe postural hypotension](#)

J Mehlsen, C Hoedersdal

UGESKRIFT FOR LAEGER 157, 295-295

[Nocturnal blood pressure increments indicate fast decline](#)

[in renal function.](#)

J Mehlsen, LJ Petersen, JR Petersen, SD Ladefoged, HA Jensen
American Journal of Hypertension 8 (994), 162A-162A

[The Effect of a Tibetan Herbal Mixture \(Padma 28\) on Walking Distance in Stable Intermittent Claudication](#) 3

J Mehlsen, H Drabaek, JR Petersen, K Wisther
FORSCHENDE KOMPLEMENTARMEDIZIN 2, 240-245

[Dependence of the arterial blood pressure on cardiac filling in severe orthostatic hypotension](#)

J Mehlsen, C Haedersdal, KH Stokholm
Ugeskrift for Laeger 157 (3), 295-297

[Somatomedin-C and procollagen aminoterminal peptide in fibromyalgia](#) 3

J Nørregaard, PM Bülow, H Volkman, J Mehlsen, BD Samsøe
Journal of Musculoskeletal Pain 3 (4), 33-40

[Does Calcium Channel Blockade and \(β-Adrenergic Blockade Affect Platelet Function and Fibrinolysis to a Varying Degree?](#) 30

G Glerup, J Mehlsen, K Winther
Journal of cardiovascular pharmacology 25 (1), 87-89

[Padma-28, et urtepraeparat, øger gangdistancen hos patienter med claudicatio intermittens](#)

H Drabaek, J Mehlsen, JR Petersen, H Himmelstrup, KF Hansen
Ugeskrift for Laeger 156 (42), 6207-9

[Padma-28, a herbal preparation, increases walking distance in patients with intermittent claudication](#) 3

H Drabaek, J Mehlsen, JR Petersen, H Himmelstrup, KF Hansen
Ugeskrift for Laeger 156 (42), 6207-6209

[Electrical impedance measured changes in thoracic fluid content during thoracentesis](#) 51

JR Petersen, BV Jensen, H Drabaek, K Viskum, J Mehlsen
Clinical Physiology 14 (4), 459-466

[Vippetest ved udredning af synkope](#)

J Mehlsen
Ugeskrift for Laeger 156 (17), 2608

[Tilt testing in syncope](#)

J Mehlsen
Ugeskrift for Laeger 156 (17), 2608-2608

[Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure](#) 8

C Haedersdal, J Mehlsen, D Stenver, B Nielsen, L Jeppesen, K Winther
Angiology 45 (3), 231-234

- [The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure](#) 24
D Stenver, L Jeppesen, B Nielsen, JD Nielsen, C Haedersdal, J Mehlsen, ...
The International Journal of Artificial Organs 17 (3), 141-145
- [Effect of supine exercise on platelet aggregation and fibrinolytic activity](#) 24
B Dag, G Gleerup, AM Bak, I Hindberg, J Mehlsen, K Winther
Clinical Physiology 14 (2), 181-186
- [Biochemical changes in relation to a maximal exercise test in patients with fibromyalgia](#) 65
J Nørregaard, PM Btilow, J Mehlsen, B Danneskiold-Samsøe
Clinical physiology 14 (2), 159-167
- [Positiv effekt af intermitterende over-og undertryk \(Vacusac\) ved claudicatio intermittens](#)
J Mehlsen, H Himmelstrup, B Himmelstrup, KFW Hansen
Ugeskrift for Laeger 156 (2), 169-71
- [Dependency of blood pressure upon cardiac filling in patients with severe postural hypotension](#) 2
J Mehlsen, C Haedersdal, KH Stokholm
Scandinavian Journal of Clinical and Laboratory Investigation 54 (4), 281-284
- [Positive effect of intermittent overpressure and underpressure \(Vacusac\) in intermittent claudication](#) 4
J Mehlsen, H Himmelstrup, B Himmelstrup, WH KF
Ugeskrift for Laeger 156 (2), 169-171
- [PADMA-28, a botanical compound, decreases the oxidative burst response of monocytes and improves fibrinolysis in patients with stable intermittent claudication](#) 35
K Winther, A Kharazmi, H Himmelstrup, H Drabaek, J Mehlsen
Fibrinolysis 8, 47-49
- [A botanical compound, Padma 28, increases walking distance in stable intermittent claudication](#) 53
H Drabaek, J Mehlsen, H Himmelstrup, K Winther
Angiology 44 (11), 863-867
- [Twitch interpolation technique in testing of maximal muscle strength: influence of potentiation, force level, stimulus intensity and preload](#) 93
PM Bülow, J Nørregaard, B Danneskiold-Samsøel, J Mehlsen
European journal of applied physiology and occupational physiology 67, 462-466
- [Systolisk blodtryk i hvile og under submaksimal og maksimal arbejdsbelastning på ergometercykel. Værdien af automatisk og auskultatorisk bestemmelse](#)

JR Petersen, H Drabaek, J Mehlsen, C Haedersdal, ML Møller
Ugeskrift for Laeger 155 (9), 631-5

[Systolic blood pressure at rest and during submaximal and maximal exercise on ergometer bicycle. The value of automatic and auscultatory determination](#) [1](#)

JR Petersen, H Drabaek, J Mehlsen, C Haedersdal, ML Møller
Ugeskrift for Laeger 155 (9), 631-635

[Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension](#) [6](#)

J Mehlsen, G Glerup, C Haedersdal, K Winther
American journal of hypertension 6 (3_Pt_2), 95S-97S

[Erythropoietin and fibrinolysis effects on platelet activity](#) [4](#)

D Stenver, B Nielsen, LL Jeppesen, JD Nielsen, K Winther, C Haedersdal, ...
The Lancet 341 (8843), 495-496

[Differential effects of \$\beta\$ -adrenoceptor partial agonists in patients with postural hypotension](#) [8](#)

J Mehlsen, C Staeager, J Trap-Jensen
European journal of clinical pharmacology 44, 7-11

[Decreased platelet activity without change in fibrinolytic activity after low dosages of fish oil](#) [14](#)

K Winther, B Myrup, G Hølmer, CE Høy, J Mehlsen, P Schnohrt
Angiology 44 (1), 39-44

[Beneficial effects of intermittent suction and pressure treatment in intermittent claudication](#) [31](#)

J Mehlsen, H Himmelstrup, B Himmelstrup, K Winther, J Trap-Jensen
Angiology 44 (1), 16-20

[Cervicobrachial syndrome: neck muscle function and effects of training](#) [41](#)

A Jordan, J Mehlsen
Journal of Musculoskeletal Pain 1 (3-4), 283-288

[RECOMBINANT-HUMAN-ERYTHROPOIETIN IMPROVES ERYTHROCYTE OSMOTIC RESISTANCE AND HAS NO EFFECT ON PLATELET-AGGREGATION ACTIVITY-A PRELIMINARY-REPORT](#)

D STENVER, L JEPPESEN, K WINTHER, C HAEDERSDAL, J MEHLSSEN, ...
KIDNEY INTERNATIONAL 41 (2), 506-506

[Xamoterol in severe congestive heart failure: long-term oral treatment, a double-blind randomised study](#) [2](#)

M Tangø, K Lyngborg, J Mehlsen, TL Svendsen, J Trap-Jensen
International journal of cardiology 34 (1), 63-68

[Central haemodynamics in patients with severe postural](#) [11](#)

[hypotension](#)

J Mehlsen, C Haedersdal, J Trap-Jensen
Clinical Physiology 11 (6), 589-601

[Reliability of impedance cardiography in measuring central haemodynamics](#) 63

J Mehlsen, J Bonde, C Stadeager, M Rehling, M Tangø, J Trap-Jensen
Clinical Physiology 11 (6), 579-588

[DOES HUMAN RECOMBINANT ERYTHROPOIETIN INFLUENCE THE HEMOSTATIC BALANCE IN PATIENTS WITH END-STAGE RENAL-FAILURE](#)

L JEPPESEN, D STENVER, J MEHLSSEN, C HAEDERSDAL, B NIELSEN, ...
THROMBOSIS AND HAEMOSTASIS 65 (6), 1354-1354

[Effects of vacuac in intermittent claudication: a controlled cross-over study](#) 15

H Himmelstrup, B Himmelstrup, J Mehlsen, J Trap-Jensen
Clinical physiology 11 (3), 263-269

[Haemodynamics in postural hypotension—effects of the \$\beta\$ -adrenoceptor partial agonist xamoterol, and pindolol](#) 3

J Mehlsen, J Trap-Jensen
European Heart Journal 11 (suppl_A), 56-58

[Influence of the renin-angiotensin system on human forearm blood flow](#) 11

C Stadeager, B Hesse, O Henriksen, F Bonde-Petersen, J Mehlsen, ...
Journal of Applied Physiology 68 (2), 527-532

[A comparison of systolic time intervals measured by impedance cardiography and carotid pulse tracing.](#) 16

J Mehlsen, J Bonde, M Rehling, M Tangø, J Trap-Jensen
Danish Medical Bulletin 37 (1), 93-95

[Effects of angiotensin blockade on the splanchnic circulation in normotensive humans](#) 31

C Stadeager, B Hesse, O Henriksen, NJ Christensen, F Bonde-Petersen, ...
Journal of Applied Physiology 67 (2), 786-791

[Increase in vagal activity during hypotensive lower-body negative pressure in humans](#) 79

K Sander-Jensen, J Mehlsen, C Stadeager, NJ Christensen, J Fahrenkrug, ...
American Journal of Physiology-Regulatory, Integrative and Comparative ...

[Substantial Effect of Acute Hydration on Blood Pressure in Patients with Autonomic Failure](#)

J MEHLSSEN, F BOESEN
Survey of Anesthesiology 32 (2), 79

[Altered balance in the autonomic nervous system in](#) 17

[schizophrenic patients](#)

BM Nielsen, J Mehlsen, K Behnke
Clinical Physiology 8 (2), 193-199

[EFFECTS OF ACUTE AND CHRONIC HYDRATION IN POSTURAL HYPOTENSION](#)

J MEHLSSEN, F BOESEN, EB ANDERSEN
CLINICAL PHYSIOLOGY 8 (1), 78-78

[RIGHT AND LEFT-VENTRICULAR FUNCTION EVALUATED BY MAGNETIC-RESONANCE IMAGING](#) 1

J MOGELVANG, H Kelbaek, J Mehlsen, J BULOW, M Stubgaard, ...
CLINICAL PHYSIOLOGY 8 (1), 79-80

[Blood-retinal barrier permeability versus diabetes duration and retinal morphology in insulin dependent diabetic patients](#) 32

B Krogsaa, H Lund-Andersen, J Mehlsen, L Sestoft
Acta Ophthalmologica 65 (6), 686-692

[Left ventricular ejection fraction determined by magnetic resonance imaging and gated radionuclide ventriculography](#) 8

J Møgelvang, C Thomsen, J Mehlsen, J Büllow, H Kelbæk, O Henriksen
American journal of noninvasive cardiology 1 (5), 278-283

[Increased sympathetic tone in forearm subcutaneous tissue in primary hypothyroidism](#) 18

HV Nielsen, K Hasselström, U Feldt-Rasmussen, J Mehlsen, ...
Clinical Physiology 7 (4), 297-302

[Substantial effect of acute hydration on blood pressure in patients with autonomic failure](#) 10

J Mehlsen, F Boesen
Clinical Physiology 7 (3), 243-246

[The Blood-retinal Barrier Permeability to Fluorescein in Normal Subjects and in Juvenile Diabetics without Retinopathy](#)

B Krogsaa, H Lund-Andersen, J Mehlsen, L Sestoft
RETINA 7 (1), 58

[Relationship between subcutaneous blood flow and absorption of lente type insulin.](#) 5

P Hildebrant, J Mehlsen, K Birch, C Kühl
Diabetes Research (Edinburgh, Scotland) 4 (4), 179-181

[Heart rate response to breathing: dependency upon breathing pattern](#) 53

J Mehlsen, K Pagh, JS Nielsen, L Sestoft, SL Nielsen
Clinical Physiology 7 (2), 115-124

[Effekten af naturmedicin og "vacuum"-behandling \(Vacusac\) hos patienter med stabil claudicatio intermittens](#)

H Himmelstrup, B Himmelstrup, J Mehlsen, J Bonde, J Trap-Jensen
Ugeskrift for Laeger 149 (13), 845-8

[ATROPINE ATTENUATES THE DECREASE IN HEART-RATE DURING HYPOTENSIVE CENTRAL HYPOVOLEMIA IN MAN](#)

K SANDERJENSEN, J MEHLSSEN, C STADEAGER, NJ CHRISTENSEN, ...
ACTA PHYSIOLOGICA SCANDINAVICA 129 (3), A40-A40

[The effect of natural medicine and vacuum therapy \(Vacusac\) in patients with stable intermittent claudication](#) 3

H Himmelstrup, B Himmelstrup, J Mehlsen, J Bonde, J Trap-Jensen
Ugeskrift for Laeger 149 (13), 845-848

[Increased cholinergic activity during gravitation-induced pre-syncope in man](#) 2

K Sander-Jensen, J Mehlsen, C Stadeager, NJ Christensen, T Schwartz, ...
The Physiologist 30 (1 Suppl), S74

[Heart rate during hypotensive central hypovolemia before and after atropine in man](#) 2

K Sander-Jensen, J Mehlsen, C Stadeager, P Bie, J Warberg
Progress in Clinical and Biological Research 236, 629-32

[Immediate haemodynamic effects of a novel partial agonist, beta 1-adrenoceptor blocking drug ICI 141,292 after intravenous administration to healthy young volunteers and ...](#) 13

J Bonde, TL Svendsen, K Lyngborg, J Mehlsen, J Trap-Jensen
British journal of clinical pharmacology 23 (1), 35-40

[Evaluation of left ventricular volumes measured by magnetic resonance imaging](#) 64

J Møgelvang, C Thomsen, J Mehlsen, G Bräckle, M Stubgaard, ...
European Heart Journal 7 (12), 1016-1021

[The blood-retinal barrier permeability to fluorescein in normal subjects and in juvenile diabetics without retinopathy](#) 25

B Krogsaa, H Lund-Andersen, J Mehlsen, L Sestoft
Acta Ophthalmologica 64 (2), 173-179

[Xamoterol, a New Selective \$\beta\$ -1-Adrenoceptor Partial Agonist, in the Treatment of Postural Hypotension](#) 31

J Mehlsen, J Trap-Jensen
Acta Medica Scandinavica 219 (2), 173-177

[IMMEDIATE HEMODYNAMIC-EFFECTS OF PRENALTEROL \(HYPRENAN\) AND XAMOTEROL \(CORWIN\) IN PATIENTS WITH SEVERE CONGESTIVE-HEART-FAILURE](#) 1

M Tango, J TRAPJENSEN, K Lyngborg, M Rehling, C Jespersen, ...

ACTA MEDICA SCANDINAVICA, 127-128

[Evaluation of left ventricular mass in vitro and in vivo with MR imaging](#)

J Mogelvang, C Thomsen, J Mehisen, O Henriksen, T Horn

The 72nd scientific assembly and annual meeting of the Radiological Society ...

[Mild mental stress in diabetes: changes in heart rate and subcutaneous blood-flow](#) 9

P Hildebrandt, J Mehlsen, L Sestoft, SL Nielsen
Clinical Physiology 5 (4), 371-376

[INCREASED SYMPATHETIC TONE IN UNTREATED HYPOTHYROIDISM](#)

K HASSELSTROM, HV NIELSEN, U FELDTRASMUSSEN, ...

ACTA ENDOCRINOLOGICA 109, 183-183

[Use of biothesiometer to measure vibration thresholds](#)

J Mehlsen

British Medical Journal (Clinical research ed.) 289 (6447), 767

[HEMODYNAMIC-RESPONSE TO STANDING IN ORTHOSTATIC HYPOTENSION-ACUTE EFFECT OF PINDOLOL](#) 1

J Mehlsen, J TRAPJENSEN

ACTA MEDICA SCANDINAVICA, 19-19

[T lymphocyte subsets in patients with newly diagnosed type I \(insulin-dependent\) diabetes: a prospective study](#) 55

K Buschard, C Röpke, S Madsbad, J Mehlsen, J Rygaard
Diabetologia 25, 247-251

[Alterations of peripheral T-lymphocyte subpopulations in patients with insulin-dependent \(type 1\) diabetes mellitus.](#) 49

K Buschard, C Röpke, S Madsbad, J Mehlsen, TB Sørensen, J Rygaard

Journal of Clinical & Laboratory Immunology 10 (3), 127-131

[A PROSPECTIVE-STUDY OF LYMPHOCYTE SUBSETS IN NEWLY DIAGNOSED TYPE-1 DIABETICS](#)

K BUSCHARD, C ROPKE, J MEHLSSEN, K BIRCH, S MADSBAD, ...

DIABETES 32, A153-A153

[The blood-retinal barrier permeability in diabetic patients](#)

B KROGSAA, H LUND-ANDERSEN, J MEHLSSEN, L SESTOFT, ...

Acta Ophthalmologica 59 (5), 689-694